WO2005065069A2 - Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease - Google Patents
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease Download PDFInfo
- Publication number
- WO2005065069A2 WO2005065069A2 PCT/US2004/022339 US2004022339W WO2005065069A2 WO 2005065069 A2 WO2005065069 A2 WO 2005065069A2 US 2004022339 W US2004022339 W US 2004022339W WO 2005065069 A2 WO2005065069 A2 WO 2005065069A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flurbiprofen
- dosage form
- unit dosage
- pharmaceutical unit
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the invention provides compositions for the therapeutic or prophylactic treatment of neurodegenerative disorders.
- the invention provides compositions comprising R-flurbiprofen and one or more pharmaceutically acceptable excipients, diluents, or carriers.
- the compositions can be used in methods of treating neurodegenerative disorders through the administration of R-flurbiprofen to certain individuals in need of such treatment.
- the invention further provides methods of improving cognitive function in a variety of Alzheimer's disease patients.
- the invention has utility for treating and preventing neurodegenerative disorders such as Alzheimer's disease, dementia, and mild cognitive impai ⁇ nent.
- the invention encompasses certain doses and dosing regimens for the prevention or treatment of Alzheimer's disease in general, and in particular in certain patient populations.
- AD Alzheimer's disease
- Dementia is a brain disorder that seriously affects a person's ability to carry out normal daily activities.
- AD Alzheimer's disease
- the causes of AD are still unknown and there is no cure.
- AD most commonly begins after the age of 60 with the risk increasing with age. Younger people can also get AD, but it is much less common. It is estimated that 3 percent of men and women ages 65 to 74 have AD. Almost half of those ages 85 and older may have the disease.
- AD is not a normal part of aging.
- Alzheimer's disease is a complex disease that can be caused by genetic and environmental factors.
- AD Alzheimer's disease
- Dr. Alois Alzheimer noticed changes in the brain tissue of a woman who had died of an unusual mental illness. In her brain tissue, he found abnormal clumps (now known as amyloid plaques) and tangled bundles of fibers (now known as neurofibrillary tangles) which, today, are considered the pathological hallmarks of AD. Other brain changes in people with AD have been discovered. For example, with AD, there is a loss of nerve cells in areas of the brain that are vital to memory and other mental abilities. Scientists have also found that there are lower levels of chemicals in the brain that carry complex messages back and forth between nerve cells. AD may disrupt normal thinking and memory by blocking these messages between nerve cells.
- Plaques and tangles are found in the same brain regions that are affected by neuronal and synaptic loss. Neuronal and synaptic loss is universally recognized as the primary cause in decline of cognitive function. The number of tangles is more highly correlated with the cognitive decline than amyloid load in patients with AD (Albert Proc. Natl. Acad. Sci. U.S.A. 93:13547-13551 (1996)). The cellular, biochemical, and molecular events responsible for neuronal and synaptic loss in AD are not known. A number of studies have demonstrated that amyloid can be directly toxic to neurons (Iversen et al. Biochem. J. 311:1-16 (1995); Weiss et al. J. Neurochem.
- AD Alzheimer's disease
- a ⁇ amyloid ⁇ protein
- FAD familial forms of AD
- FAD familial Alzheimer's disease
- the first of the 3 FAD genes codes for the AjS precursor, amyloid precursor protein (APP) (Selkoe J. Biol. Chem. 271(31):18295-8 (1996)). Mutations in the APP gene are very rare, but all of them cause AD with 100% penetrance and result in elevated production of either total AjS or A
- the other two FAD genes code for presenilin 1 and 2 (PSl, PS2) (Hardy Proc. Natl. Acad. Sci. U.S.A. 94(6):2095-7 (1997)).
- PSl, PS2 presenilin 1 and 2
- the presenilins contain 8 transmembrane domains and several lines of evidence suggest that they are involved in intracellular protein trafficking.
- Cyclooxygenases are major Alzheimer's disease drug targets due to the epidemiological association of NSATD use, whose primary target are cycloxygenases, with a reduced risk of developing Alzheimer's disease (see, e.g., Hoozemans et al. Curr. Drug Targets 4(6):461-8 (2003) and Pasinetti et al. J. Neurosci. Res. 54(l):l-6 (1998)).
- the epidemiological studies have indicated that chronic NSATD use appears to reduce the risk of acquiring Alzheimer's disease and/or delay the onset of the disease (see e.g., McGeer et al. Neurology 47(2):425-432 (1996); and Etminan et al. BMJ.
- COX-2 selective inhibitors are attractive candidates for long-term drug use since they do not inhibit COX-1 and appear to be less toxic.
- COX-2 overexpression was related to the neuropathology of AD (Xiang et al. Neurobiol. Aging 23 :327-34 (2002)).
- recent clinical trials of specific NSAIDs have called into question the hypothesis the hypothesis that anti-inflammatory drugs are useful for the treatment or prevention of Alzheimer's disease. It was reported that rofecoxib, a COX-2 selective NSATD, at 25 mg daily, failed to show efficacy for treating AD.
- gamma-secretase inhibitors which were designed to alter processing of APP, have turned out to be toxic compounds not likely to be suitable for chronic human use. See De Strooper et al. Nature 398:518-522 (1999); Wong et al. J. Biol. Chem. 279:12876-12882 (2004); and Hadland et al. PNAS 98(13):7487-91 (2001). Thus, it is not clear if gamma-secretase inhibitors are a realistic treatment/prevention option. Indeed, as noted recently, mutations in PS-1 associated with AD may cause the disease not through altering A ⁇ processing, but rather by affecting calcium homeostasis (Mattson, Nature 442:385-386 (2003)).
- NSAIDs such as ibuprofen and aspirin
- AD Alzheimer's disease
- COX cyclooxygenase
- NSAIDs reduce risk for certain cancers and Alzheimer's disease by affecting the COX enzymes.
- Other explanations include mediation of apoptosis, modulation of growth factors, and modulation of the nuclear factor kappa B pathway (NF- ⁇ B).
- United States Patent No. 5,643,960 to Brietner et al. reports the use of COX inhibiting NSAIDs to delay the onset of Alzheimer's symptoms.
- United States Patent No. 6,025,395 to Brietner et al. relates to the use of COX inhibiting NSAIDs.
- Flurbiprofen is a racemic non-steroidal anti-inflammatory drug (NSATD) having a chemical name of (R,S)-(2-fluoro-biphenylyl) propionic acid. 50 milligram (mg) and 100 mg racemic flurbiprofen tablets are marketed as ANSATD® and FROBEN® for the treatment of chronic inflammatory disease.
- NSATD non-steroidal anti-inflammatory drug
- tacrine (Cognex ® ), donepezil (Aricept ® ), rivastigmine (Exelon ® ), and galantamine (Reminyl ® )
- memantine Another drug, memantine, was recently approved for treating moderate-to-severe AD. More recently it was reported that memantine showed efficacy in treating mild-to-moderate AD. Memantine is a NMDA receptor antagonist.
- the drugs currently used for treating AD including memantine and the acetylcholine esterase inhibitors, are marginally efficacious and have undesirable side-effects. Thus, there is a large unmet need for better and safer drugs.
- the invention relates to a pharmaceutical composition having R- flurbiprofen as the active ingredient. More specifically, the invention relates to specific dosage formulations or doses (i.e., unit dosage forms) of R-flurbiprofen useful in the treatment or prevention of Alzheimer's disease, e.g., 400 mg, 800 mg, 1200 mg and 1600 mg compositions or daily doses. As described in more detail below, when the dosage for, for example, the 400 mg dosage form, is orally administered in a single dose of the composition of the invention to a fasting subject, it provides a C max (maximum plasma concentration after administration) of about 30- 95 micrograms ( ⁇ g) per milliliter (mL).
- C max maximum plasma concentration after administration
- composition When the composition is administered twice daily (b.i.d) for at least 4 months, preferably at least 8 months, and more desirably at least 1 year, it provides an improvement or lessening in decline of cognitive function as characterized by cognition tests, measures of global function, activities of daily living, behavior, biochemical disease marker progression, changes in brain volume, and/or plaque pathology.
- cognition tests are those which are capable of measuring cognitive decline in a patient or group of patients.
- compositions of the invention are formulated with one or more pharmaceutically acceptable excipients, salts, or carriers.
- the pharmaceutical compositions of the invention are delivered orally, preferably in a tablet or capsule dosage form.
- the R-flurbiprofen compositions of the invention can be used in methods for treating, preventing, and prophylaxis against neurodegenerative disorders such as Alzheimer's disease.
- the invention provides a dosage comprising R-flurbiprofen in an amount of about 400 mg to about 800 mg per dose.
- Oral administration of a single dose to a fasting subject provides a C max of about 30-95 ⁇ g per mL.
- Oral administration of the composition of this aspect of the invention twice daily (b.i.d) for at least 4 months, preferably at least 8 months, and more desirably at least 1 year provides an improvement or lessening of decline in cognitive function as characterized by cognition tests. It is preferred that the improvement in decline in cognitive function is at least 25% as compared to a control, more preferably at least 40%, and even more desirably at least 60%.
- the control may be a plurality of individuals treated with placebo, or may be the expected decline in a test of cognition over a period of time.
- an individual having probable mild-to-moderate Alzheimer's disease, who is treated with placebo is expected to score approximately 5.5 points higher on the ADAS-cog test after a specified period of time of treatment (e.g., 1 year) whereas an individual treated with a composition of the invention for the same period of time will score only about 2.2 points higher on the ADAS-cog scale, e.g., will show about a 60% improvement in decline; or only about 3.3 points higher, e.g., will show about a 40% improvement in decline in cognitive function.
- the actual numeric score will depend upon the test given. For example, a higher number on the MMSE indicates better cognition, and a lower score (i.e., below 26) indicates some degree of dementia.
- the oral dose is provided in capsule or tablet form.
- the dosage is provided as a pharmaceutical composition composed of R-flurbiprofen, a pharmaceutically acceptable salt, a release agent, and optionally additional ingredients.
- the dosage is provided as a pharmaceutical composition in a unit dosage form that is a tablet composed of R- flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
- the dosage is provided as a pharmaceutical composition in a unit dosage form that is a coated tablet composed of R-flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate, all coated in a mixture of lactose monohydrate, hydroxyl propyl methyl cellulose, titanium dioxide, tracetin/glycerol triacetate, and iron oxide.
- the dosage is provided as a pharmaceutical composition in a unit dosage form that is a capsule composed of R- flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
- the invention provides for a method of treating an individual having, or suspected of having, Alzheimer's disease, comprising administering R-flurbiprofen, wherein said administration provides a C max of about 30 to about 95 ⁇ g per mL. In a more specific embodiment, said C ma is between 40 and 80 ⁇ g per mL.
- the invention further provides a method of improving a decline in a measure of cognitive function of an individual comprising administering R- flurbiprofen to said individual, wherein said administering results in the reduction of the decline in said measure of cognitive function as compared to a control.
- said control is the decline in said measure of cognitive function in an individual not given R-flurbiprofen, wherein said individual has or is suspected of having Alzheimer's disease.
- said control is the average decline in said measure of cognitive function in a plurality of individuals not given flurbiprofen, wherein said individuals have or are suspected of having Alzheimer's disease.
- said reduction in said decline in said measure of cognitive function is at least 25% compared to said control.
- said reduction in said decline in said measure of cognitive function is at least 40% compared to said control.
- said improvement in said decline in said measure of cognitive function is at least 60% compared to said control.
- said measure of cognitive function is an ADAS-cog test.
- said reduction in decline is about 2.2 points in the ADAS-cog test over one year.
- said reduction in decline is about 3.3 points in the ADAS-cog test over one year.
- said R-flurbiprofen is administered in a dose of about 400 mg twice daily.
- said R-flurbiprofen is administered in a dose of about 800 mg twice daily.
- the invention provides a dosage having R-flurbiprofen in an amount of about 400 mg to about 800 mg per dose that is suitable for providing an improvement or lessening of decline in biochemical disease marker progression.
- Oral administration of a single dose to a fasting subject provides a C max of about 30- 95 ⁇ g per mL.
- Oral administration of the composition of this aspect of the invention twice daily (b.i.d) for at least 4 months, preferably at least 8 months, and more desirably at least 1 year provides an improvement or lessening of decline in biochemical disease marker progression.
- biochemical disease markers include, for example, amyloid beta peptide (A ⁇ ), A/3 2 , and tau. It is preferred that the lessening in decline in biochemical disease marker progression is at least 10 % as compared to individuals treated with placebo, more preferably at least 20 %, and more desirably at least 40 %.
- the oral dose is provided in capsule or tablet form.
- the dosage is provided as a pharmaceutical composition that is composed of R-flurbiprofen, a pharmaceutically acceptable salt, a release agent, and optionally additional ingredients.
- the dosage is provided as a pharmaceutical composition in a unit dosage form that is a tablet composed of R- flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
- the dosage is provided as a pharmaceutical composition in a unit dosage form that is a coated tablet composed of R-flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate, all coated in a mixture of lactose monohydrate, hydroxyl propyl methyl cellulose, titanium dioxide, tracetin/glycerol triacetate, and iron oxide.
- the dosage is provided as a pharmaceutical composition in a unit dosage form that is a capsule composed of R- , flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
- the invention provides for a method of improving or lessening the rate of decline in (i.e., reversing or slowing the progression of), Alzheimer's disease in an individual having, or suspected of having, Alzheimer's disease, comprising administering R-flurbiprofen to said individual. Disease progression may be monitored by one or more Alzheimer's disease markers.
- said administration provides a Cm ax of about 30 to about 95 ⁇ g per mL.
- said C max is between 40 and 80 ⁇ g per mL.
- said administration is continued at least once a day for at least four months.
- said administration is continued at least once a day for at least eight months or for at least twelve months.
- said disease marker is amyloid beta peptide (A ⁇ ), A/3 42 , or tau.
- said R-flurbiprofen is administered in a dose of about 400 mg twice daily. In another specific embodiment, said R-flurbiprofen is administered in a dose of about 800 mg twice daily.
- the invention provides a dosage having R-flurbiprofen in an amount of about 400 mg to about 800 mg per dose that is suitable for providing an improvement or lessening of decline in plaque pathology associated with AD.
- Oral administration of a single dose to a fasting subject provides a C max of about 30-95 ⁇ g per mL.
- the lessening in, i.e., improvement in, decline in plaque pathology is at least 10% as compared to individuals treated with placebo, preferably at least 20%, and even more desirably at least 40%.
- Plaque pathology can be assessed by a variety of techniques including, for example, positron emission tomography.
- the oral dose is provided in capsule or tablet form.
- the dosage is a provided as a pharmaceutical composition composed of R-flurbiprofen, a pharmaceutically acceptable salt, a release agent, and optionally additional ingredients.
- the dosage is provided as a pharmaceutical composition in a unit dosage form that is a tablet composed of R-flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
- the dosage is provided as a pharmaceutical composition in a unit dosage form that is a coated tablet composed of R-flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate all coated with a mixture of lactose monohydrate, hydroxyl propyl methyl cellulose, titanium dioxide, tracetin/glycerol triacetate and iron oxide.
- the invention provides for a method of improving, or lessening a decline in, plaque pathology associated with Alzheimer's disease in an individual having, or suspected of having, Alzheimer's disease, comprising administering R-flurbiprofen to said individual.
- said administration provides a C max of about 30 to about 95 ⁇ g per mL. In a more specific embodiment, said C max is between 40 and 80 ⁇ g per mL.
- said administration is continued at least once a day for at least four months.
- said administration is continued at least once a day for at least eight months or for at least twelve months.
- said R-flurbiprofen is administered in a dose of about 400 mg twice daily. In another specific embodiment, said R-flurbiprofen is administered in a dose of about 800 mg twice daily.
- the invention provides a method of treating Alzheimer's disease comprising administering to a patient in need of such treatment, a pharmaceutical composition comprising an effective amount of R-flurbiprofen and one or more pharmaceutically acceptable excipients, salts, or carriers.
- a dose of an effective amount upon oral administration to a fasting subject, provides a C ma ⁇ of about 30-95 ⁇ g per mL.
- Oral administration of the composition of this aspect of the invention twice daily for at least 4 months, preferably at least 8 months, and more desirably at least 1 year provides an improvement or lessening in decline of cognitive function as characterized by cognition tests, biochemical disease marker progression, and or plaque pathology.
- the oral dose is provided in capsule or tablet form.
- a patient in need of treatment is administered an Alzheimer's disease treating effective amount of a pharmaceutical composition having R-flurbiprofen and one or more pharmaceutically acceptable salts, excipients and carriers.
- the method of this aspect of the invention involves identifying individuals likely to have mild-to-moderate Alzheimer's disease. Individuals having probable mild-to-moderate Alzheimer's disease can be diagnosed by any method available to the ordinary artisan skilled is such diagnoses. For example, diagnosis can be according to DSM-TV (TR) and/or meets NLNCDS- ADRDA criteria for probable AD.
- individuals with probable mild-to-moderate AD take an oral dose of a pharmaceutical composition, twice-a-day (e.g., two tablets containing 400 mg of R-flurbiprofen twice daily, or one tablet containing 400 mg of R-flurbiprofen twice daily) for at least 90 days, preferably 120 days, more preferably at least 180 days and even more desirably at least 365 days.
- Individuals undergoing such treatment are likely to see an improvement or lessening in decline of cognitive function, an improvement or lessening in decline in biochemical disease marker progression, and/or an improvement or lessening in decline in plaque pathology.
- a lessening in decline in cognitive function can be assessed using test of cognitive function like the ADAS- cog.
- an individual treated with placebo having probable mild-to- moderate Alzheimer's disease is expected to score approximately 5.5 points higher on the ADAS-cog test after a specified period of time of treatment (e.g., 1 year) whereas an individual treated with the composition of this aspect of the invention for the same period of time will score approximately 2.2 points higher on the ADAS-cog scale, i.e., a 60% decrease in decline, or 3.3 points higher, i.e., a 40% decrease in decline in cognitive function.
- the invention provides a method of preventing the onset of Alzheimer's disease comprising administering to a patient in need of or desiring such treatment, a pharmaceutical composition comprising an effective amount of R- flurbiprofen and one or more pharmaceutically acceptable excipients.
- a dose of an effective amount upon oral administration to a fasting subject provides a C ma of about 30-95 ⁇ g per mL.
- an individual desiring or needing preventative treatment against the onset of AD is administered twice daily a dose having from about 400 mg to about 800 mg of R-flurbiprofen.
- the oral dose is provided in capsule or tablet form.
- the preventive treatment is preferably maintained as long as the individual continues to desire or need the treatment.
- Individuals needing or desiring preventative treatment against AD can be those having risk factors for developing AD.
- risk factors for developing AD can be genetic factors or environmental factors.
- the risk factor is age. Genetic risk factors can be assessed in a variety of ways, such as ascertaining the family medical history of the individual, or performing a genetic test to identify genes that confer a predisposition for developing AD. Additionally, risk factors can be assessed by monitoring genetic and biochemical markers.
- the invention provides a method of decelerating the onset of Alzheimer's disease comprising administering to a patient in need of such treatment, a pharmaceutical composition comprising an effective amount of R- flurbiprofen and one or more pharmaceutically acceptable excipients, wherein a dose of an effective amount upon oral administration to a fasting subject provides a C max of about 30-95 ⁇ g per mL.
- Oral administration of the R-flurbiprofen composition twice daily for at least 4 months, preferably 8 months, and more desirably 1 year provides a deceleration in decline of cognitive function, biochemical disease marker progression, and/or plaque pathology.
- an individual having mild cognitive impairment that is likely progress to AD is identified.
- the individual can be in the prodromal stage of AD development.
- a preventive treatment regimen is prescribed for the patient.
- the preventive treatment regimen involves administering to the individual in need or desiring such treatment a pharmaceutical composition sufficient to decelerate the onset of Alzheimer's disease.
- the R-flurbiprofen composition for use in this aspect of the invention is designed in such as to be suitable for chronic long-term use with a prophylactic effect.
- the invention provides a method of selecting a regimen for treating cognitive decline in an individual desiring such treatment.
- the method of this aspect involves evaluating risk factors for cognitive decline.
- Evaluation of risk factors can include genetic testing for predisposing genes, alleles, and polymorphisms. Risk factors also refer to environmental factors like stroke, brain injury, age, and diet.
- risk factors also refer to environmental factors like stroke, brain injury, age, and diet.
- a particular treatment regimen is selected for treating cognitive decline. For example, mutations in a Familial Alzheimer's disease genes such as APP, PSl or PS2, are a risk factor.
- Another risk factor for cognitive decline is age. Head trauma is another risk factor for cognitive decline.
- a physician will prescribe a particular therapeutic treatment or prophylactic treatment suitable for the patient.
- the invention relates to a method for improving cognitive function. More particularly, this aspect of the invention provides a method for improving cognitive function in individuals experiencing cognitive decline such as that experienced by Alzheimer's disease patients.
- the invention is based on the discovery that Alzheimer's disease patients that have experienced cognitive decline as a result of the disease can experience an improvement in cognition when administered a cognition improving effective amount of a pharmaceutical composition having R- flurbiprofen as the active ingredient.
- the invention provides a method for improving cognitive function in individuals experiencing cognitive decline.
- an individual in need of or desiring treatment e.g., a patient having Alzheimer's disease or mild cognitive impairment
- a composition having R-flurbiprofen in an amount of about 100 mg to about 1800 mg per day for at least 4 weeks, preferably at least 4 months, and more preferably at least 6 months.
- the composition used in the invention is formulated with one or more pharmaceutically acceptable excipients, salts, or carriers.
- the pharmaceutical composition can be delivered orally, preferably in a tablet or capsule dosage form.
- Oral administration of a single dose of the cognition improving effective amount of R-flurbiprofen to a fasting subject provides a C max of about 30-95 ⁇ g per mL.
- Oral administration of the R-flurbiprofen composition twice daily (b.i.d) for at least 4 weeks, preferably at least 4 months, even more preferably at least 6 months, and more desirably at least 1 year, provides an improvement in cognitive function as characterized by cognition tests. It is preferred that the improvement in cognitive function is statistically significant as compared to individuals treated with placebo.
- the oral dose is provided in capsule or tablet form.
- the dosage is provided as a pharmaceutical composition composed of R-flurbiprofen, a pharmaceutically acceptable salt, a release agent, and optionally additional ingredients.
- FIG. 1 depicts a One Compartment Pharmacokinetic Model used in a pharmacokinetic study as described in Example 5.
- FIG. 2 depicts pharmacokinetic results obtained from the study disclosed in Example 5.
- Graph presents the mean concentration of a 200 b.i.d., 400 b.i.d., or 800 b.i.d. dose in the plasma of individuals from 0 to 25 hours after administration.
- Circles actual mean plasma concentrations for each dosage group.
- Line predicted plasma concentration for each dosage group using the model of FIG. 1.
- the invention relates to a pharmaceutical composition having R- flurbiprofen as the active ingredient.
- the invention encompasses oral compositions that, upon administration of a dose of said pharmaceutical composition to a subject, provides pharmacokinetic and therapeutic characteristics particularly useful in the methods of the invention.
- the invention also encompasses the use of the inventive composition according to the treatment regimens of the invention by an individual desiring or needing such treatment, thus providing an improvement or lessening in decline of cognitive function, biochemical disease marker progression, and/or plaque pathology associated with neurodegenerative disorders such as AD.
- the composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts, or carriers.
- the pharmaceutical composition of the invention is delivered orally, preferably in a tablet or capsule dosage form.
- the R-flurbiprofen composition of the invention can be used in methods for treating, preventing, and prophylaxis against neurodegenerative disorders such as Alzheimer's disease.
- preventing an increase in a symptom refers to both not allowing a symptom to increase or worsen, as well as reducing the rate of increase in the symptom.
- a symptom can be measured as the amount of particular disease marker, i.e., a protein.
- Preventing an increase means that the amount of the protein does not increase or that the rate at which it increases is reduced.
- treating Alzheimer's disease refers to a slowing of or a reversal of the progress of the disease in an individual that has been diagnosed as having, or has one or more indicia of, mild Alzheimer's disease, as diagnosed by a test of cognition. Treating Alzheimer's disease includes reducing, lessening or improving one or more of the symptoms of the disease.
- preventing Alzheimer's disease refers to a slowing of, or stopping, the onset of the disease or of one or more of the symptoms thereof. In particular, the term means slowing or stopping the onset of one or more aspects of Alzheimer's disease that would otherwise lead to a diagnosis of at least mild Alzheimer's disease on one or more tests of cognition.
- the term "with reduced gastrointestinal toxicity" as used herein means that the administration of R-flurbiprofen is less ulcero genie to the gastrointestinal tract of the human or other mammal than the corresponding racemate, or S -flurbiprofen.
- One measure of ulcerogenic activity is the small bowel ulcer score.
- a rat is treated daily through oral administration of the R-flurbiprofen for 30 days. At the end of the 30 days, the rat is sacrificed and the intestines removed. Lesions of appreciable size in the mucosa are measured. A cumulative score equaling the sum of the diameters of the ulcers measured are reported as the ulcer score.
- an ulcer score essentially equal to that of a control rat, or a reduction of the ulcer score of at least 50 to 90%, preferably at least 80%, as compared to the corresponding S-enantiomer or NSATD racemate, is considered a reduction in gastrointestinal toxicity.
- the term "with reduced gastrointestinal toxicity" refers the ability to administer a lower amount of flurbiprofen such that unwanted gastrointestinal toxicity side-effects are reduced.
- R-flurbiprofen refers to the R-enantiomer of the non-steroidal anti-inflammatory drug flurbiprofen.
- R-flurbiprofen can be administered as a substantially pure R-enantiomer or as part of a racemic mixture.
- the amount of R-flurbiprofen is adjusted to avoid adverse effects associated with the S enantiomer of flurbiprofen.
- substantially free of the (S)-stereoisomer as used herein means that the composition contains a greater proportion of the R-enantiomer in relation to the S-enantiomer of flurbiprofen.
- the term "substantially free of its S-stereoisomer” as used herein means that the composition contains at least 90% by weight of R-flurbiprofen and 10% by weight or less of S-flurbiprofen; in a more preferred embodiment at least 95% R-flurbiprofen and 5% by weight or less of its S-enantiomer. These percentages are based on the total amount of flurbiprofen present in the composition. In the certain preferred embodiments the term "substantially free of its S-stereoisomer” means that the composition contains approximately 99% by weight of R-flurbiprofen, and 1% or less of S-flurbiprofen.
- the term "substantially free of its S-stereoisomer” as used herein means that the composition contains greater than 99% by weight of the R-enantiomer of flurbiprofen, again based on the total amount of flurbiprofen present.
- the terms “substantially optically pure R-isomer of flurbiprofen,” “optically pure R-isomer of flurbiprofen,” “optically pure R-flurbiprofen” and “R-isomer of flurbiprofen” are also encompassed by the above- described amounts.
- substantially free indicates that the amount of S- flurbiprofen, if any, present in the composition is insufficient to elicit an adverse effect in the patient to whom the composition is administered or, at most elicits an adverse effect that is tolerable to the patient and is outweighed by the beneficial effect or effects.
- unit dosage form refers to a physically discrete unit, such as a capsule or tablet suitable as a unitary dosage for a human patient.
- Each unit contains a predetermined quantity of R-flurbiprofen that was discovered as a result of this invention to produce the desired pharmacokinetic profile which yields the desired therapeutic effect.
- the dosage unit is composed of R-flurbiprofen in association with at least one pharmaceutically acceptable carrier, salt, excipient, or combination thereof.
- the term "dose” or “dosage” refers the amount of active ingredient that an individual takes or is administered at one time.
- an 800 mg R-flurbiprofen dose refers to, in the case of a twice-daily dosage regimen, a situation where the individual takes 800 mg R-flurbiprofen in the morning and 800 mg R-flurbiprofen in the evening.
- the 800 mg R-flurbiprofen dose can be divided into two or more dosage units, e.g., two 400 mg R-flurbiprofen tablets or two 400 mg R-flurbiprofen capsules.
- ⁇ indicates a range of +/- 20%.
- about 400 mg R-flurbiprofen means a range of from 320 mg to 480 mg R-flurbiprofen.
- decline when used to characterize a disease such as Alzheimer's, or a symptom or marker thereof, means a worsening or progression of the disease, symptom or marker thereof over time from less-advanced to more- advanced. In the case of Alzheimer's disease, a decline indicates a worsening or increase in the severity of one or more behavioral, cognitive, biochemical or clinical parameters of the condition.
- Decline also indicates a progression of one or more scores on a cognition test that indicate a worsening of the condition, regardless of whether the actual, raw scores increase or not.
- Alzheimer's disease and "AD” are equivalent.
- any individual having, or suspected of having, a neurodegenerative disorder, such as Alzheimer's disease maybe treated using the compositions and methods of the present invention.
- Individuals who would particularly benefit from the compositions and methods of the invention include those individuals diagnosed as having mild to moderate Alzheimer's disease according to a medically-accepted diagnosis, such as, for example the NTNCDS-ADRDA criteria. Progression of the disease may be followed by medically accepted measure of cognitive function, such as, for example, the Mini-Mental State Exam (MMSE; see Mohs et al. Int. Psychogeriatr.
- MMSE Mini-Mental State Exam
- ADCS-ADL Alzheimer's Disease Cooperative Study Activities of Daily Living scale
- DSM-TV Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition
- NTNCDS-ADRDA criteria See Folstein et al. J. Psychiatr. Res. 12:189-198 (1975)
- Individuals diagnosed as having probable AD can be identified as having a mild-to-moderate form of the disease by an accepted measure of cognitive function such as the MMSE.
- methods that allow for evaluating different regions of the brain and estimating plaque and tangle frequencies can be used. These methods are described by Braak et al.
- the severity of AD is generally determined by one of the initial tests provided above. For example, MMSE scores of 26-19 indicate mild AD, while scores from 18-10 indicate moderate AD.
- diagnoses of Alzheimer's disease based on these tests are recorded as presumptive or probable, and may optionally be supported by one or more additional criteria.
- a diagnosis of Alzheimer's disease may be supported by evidence of a family history of AD; non-specific changes in EEG, such as increased slow- wave activity; evidence of cerebral atrophy on CT with progression documented by serial observation; associated symptoms such as depression, insomnia, incontinence, delusions, illusions, hallucinations, catastrophic verbal, emotional or physical outbursts, sexual disorders, weight loss, and/or attendant neurologic abnormalities, such as increased muscle tone, myoclonus or gait disorder, etc.
- amyloid deposits may be detected through the use of positron emission tomography (PET) using an amyloid-specific tracer such as Pittsburgh Compound-B (PIB).
- PET positron emission tomography
- PIB Pittsburgh Compound-B
- Increased amyloid deposits in the frontal, parietal, temporal and occipital cortices, and in the striatum, relative to normal brain tissue, as visualized, for example by PTB support a diagnosis of AD.
- a greater number and density of amyloid deposits indicates more advanced AD.
- the invention encompasses the treatment of an individual preferably having mild to moderate AD, to the extent that individual has AD, whether or not one or more non- AD neurodegenerative diseases or conditions are previously, concurrently or subsequently diagnosed.
- the compounds and methods of the present invention are useful for individuals who have received prior medication for AD, as well as individuals who have received no prior medication for AD, and is useful for individuals currently receiving medication for AD other than R-flurbiprofen, and for individuals not receiving medication for AD other than R-flurbiprofen.
- individuals of any age may be treated by the methods of the invention, with the pharmaceutical compositions of the invention; however, the invention encompasses a preferred embodiment for treating or preventing Alzheimer's disease in individuals between the ages of 55 and 80.
- individuals treated by the therapeutic or prophylactic methods of the invention may be from 55 to 70 years of age, 60 to 80 years of age, 55 to 65 years of age, 60 to 75 years of age, 65 to 80 years of age, 55 to 60 years of age, 60 to 65 years of age, 65 to 70 years of age, 70 to 75 years of age, 75 to 80 years of age, or 80 years old and older.
- the invention provides a method of treating an individual known or suspected of having Alzheimer's disease comprising administering an effective amount of R-flurbiprofen.
- said individual is diagnosed as having mild to moderate Alzheimer's disease.
- said individual is diagnosed by a cognitive test as having mild to moderate AD.
- said cognitive test is the Mini- Mental State Exam (MMSE).
- MMSE Mini- Mental State Exam
- said individual has a score in said MMSE of from 26 to 19, inclusive.
- said individual has a score in said MMSE of from 18 to 10, inclusive.
- said individual has a score in said MMSE of 26 to 10, inclusive.
- the invention provides a method of treating an individual known or suspected of having Alzheimer's disease comprising administering an effective amount of R-flurbiprofen, wherein said individual is concurrently taking a second drug for the treatment of Alzheimer's disease.
- said individual has been diagnosed as having mild to moderate Alzheimer's disease.
- said second drug is an acetylcholinesterase (AChE) inhibitor.
- said AChE inhibitor is Galanfhamine (galantamine, Reminyl); E2020 (Donepezil, Aricept); Physostigmine; Tacrine (tetrahydroaminoacridine, THA); Rivastigmine; Phenserine; Metrifonate (Promem); or Huperazine, or a combination of any of the foregoing.
- said second drug is a drug other than an acetylcholinesterase inhibitor.
- the method or compositions of the invention are used in patients or individuals undergoing therapy with Aricept. The invention also encompasses methods of treating patients refractory to, or who no longer show improvement with, conventional AD therapy.
- said individual is concurrently taking a non-drug substance for the treatment of Alzheimer's disease.
- said non-drug substance is an anti-oxidant.
- said anti-oxidant is vitamin C or vitamin E.
- said vitamin C is taken in a dose of 500-1000 mg per dose of R-flurbiprofen.
- said vitamin E is taken in a dose of 400-800 IU per dose of R- flurbiprofen.
- the invention encompasses the use of one or more such anti-oxidants as an adjunct to therapy for Alzheimer's disease, and not primarily as a nutritional supplement.
- the invention provides a method of treating an individual diagnosed as having mild to moderate Alzheimer's disease comprising administering an effective amount of R-flurbiprofen, wherein said individual has, prior to taking R-flurbiprofen, taken a second drug for the treatment of Alzheimer's disease.
- said second drug is an acetylcholinesterase (AChE) inhibitor.
- said anti-oxidant is vitamin C or vitamin E.
- said vitamin C is taken in a dose of 500-1000 mg per dose.
- said vitamin E is taken in a dose of 400-800 IU per dose.
- the invention encompasses the use of one or more such anti-oxidants as an adjunct to therapy for Alzheimer's disease, and not primarily as a nutritional supplement.
- the invention encompasses a preferred method wherein R-flurbiprofen is used in individuals who do not have: (1) a history in the past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness and or immediate confusion after the injuries; (2) DSM-TV (TR) criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse; (3) a history of hypersensitivity to flurbiprofen or other NSAIDs including COX-2 specific inhibitors; (4) a history of upper GI bleeding requiring transfusion or surgery within the past 3 years; (5) active gastric or duodenal ulcer disease; (6) a history of NSATD-associated ulcers; (7) active malignancy, or a history of active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin; (8) chronic or acute renal, hepatic or metabolic disorder defined by creatinine > 1.5 mg/dL, AST > 2.5 x Upper Limit of Normal (ULN); or
- the invention provides a method of slowing cognitive decline in an individual suspected of having mild cognitive impairment (MCI) comprising administering to the individual an effective amount of R- flurbiprofen.
- Mild cognitive impairment is a clinical condition between normal aging and Alzheimer's disease characterized by memory loss greater than expected for the particular age of the individual yet the individual does not meet the currently accepted definition for probable Alzheimer's disease. See, e.g., Petersen et al. Arch. Neurol. 58:1985-1992 (2001); Petersen Nature Rev. 2:646-653 (2003); and Morris et al. J Mol. Neuro. 17:101-118 (2001).
- an individual suspected of having or diagnosed with MCI is treated twice daily with a composition having from 400 mg to about 800 mg of R-flurbiprofen per dose for at least 4 weeks, at least 4 months, preferably at least 8 months, and more desirably at least 1 year.
- patients having MCI first complain of or have a loss of memory.
- an individual associated with the patient can corroborate the memory deficit.
- general cognition is not sufficiently impaired to cause concern about more widespread cognitive disorder and although daily living activities may be affected that are not significantly impaired and the patients are not demented.
- Individuals having or suspected of having MCI that are treated according to this embodiment can expect to slow cognitive decline and/or progression to probable AD.
- the invention is based on the discovery that a dosage having R-flurbiprofen in an amount of about 400 mg to about 800 mg per dose provides a PK profile believed to be effective in treating mild-to-moderate AD. Without wishing to be bound by theory, it is believed that PK profile obtained maximizes therapeutic effects while minimizing side-effects thereby providing maximum benefit to the patient.
- the dose can be provided twice daily, in a single or multiple dosage units (i.e., tablets or capsules) of about 350 mg R-flurbiprofen, 400 mg R-flurbiprofen, 450 mg R- flurbiprofen, 500 mg R-flurbiprofen, 550 mg R-flurbiprofen, 600 mg R-flurbiprofen, 650 mg R-flurbiprofen, 700 mg R-flurbiprofen, 750 mg R-flurbiprofen, 800 mg R- flurbiprofen, or 850 mg R-flurbiprofen.
- a single or multiple dosage units i.e., tablets or capsules
- the dose is 400 mg; thus, a preferred composition of the invention comprises 400 mg R-flurbiprofen and a carrier or vehicle suitable for oral administration, e.g., in tablets or capsules.
- Another preferred dose is 800 mg of R-flurbiprofen, and a preferred composition of the invention comprises 400 mg R-flurbiprofen and a carrier or vehicle suitable for oral administration, e.g., in tablets or capsules.
- the compositions are substantially free of S-flurbiprofen.
- oral administration of a single dose to a fasting subject provides a C ma ⁇ of about 25-150 ⁇ g per mL per dose, and, preferably, between 30-95 ⁇ g per mL per dose.
- Administration of a single dose of the compositions of the invention to a fasting subject provides an AUC (area under curve of concentration versus time; total drug exposure) of from about 200 hr» ⁇ g/mL to about 600 hr» ⁇ g/mL.
- the t max time to C max
- t max is achieved at about 2 hours after administration.
- the t 2 (half-life) is from about 3.75 to about 8.5 hours.
- a low dose regimen provides R- flurbiprofen to the individual in a dosage of about 200 mg.
- a low dose regimen can, for example, be used after the dosing regimen of 400 to 400 b.i.d.
- Oral administration of a dose, twice daily for at least 4 months, preferably 8 months, and more preferably 1 year, provides an improvement or lessening of decline in cognitive function, biochemical disease marker progression, and/or plaque pathology.
- the composition of the invention are substantially free of the S- stereoisomer of flurbiprofen.
- substantially free of the S-stereoisomer means at least 90% by weight R-flurbiprofen to 10% by weight or less of S- flurbiprofen of the total flurbiprofen (S + R flurbiprofen) in said pharmaceutical composition.
- substantially free of the S-stereoisomer means at least 95%o by weight R-flurbiprofen to 5% by weight or less of S-flurbiprofen of the total flurbiprofen (S + R flurbiprofen) in the pharmaceutical composition.
- substantially free of the S-stereoisomer means at least 99 % by weight R-flurbiprofen to 1 % by weight or less of S-flurbiprofen of the total flurbiprofen (S + R flurbiprofen) in the pharmaceutical composition. In yet another aspect, substantially free of the S-stereoisomer means at least 99.9 % by weight R- flurbiprofen to 0.1 % by weight or less of S-flurbiprofen of the total flurbiprofen (S + R flurbiprofen) in the pharmaceutical composition.
- a preferred dosage form is a tablet. In another aspect, a preferred dosage form is a capsule.
- the composition provides an improvement or lessening in decline in biochemical disease marker progression, plaque pathology, quality of life indicators or combinations of any disease parameters.
- the decline in cognitive function can be characterized by cognition tests. It is preferred that the lessening in decline in cognitive function is at least 25% as compared to individuals treated with placebo, more preferably at least 40%, and even more preferably at least 60%.
- an individual treated with placebo having probably mild-to-moderate Alzheimer's disease is expected to score approximately 5.5 points higher on the ADAS-cog test after a specified period of time (e.g., 1 year) whereas an individual treated with a composition of the invention for the same period of time will score only approximately 3.3 points higher on the ADAS- cog scale, i.e., will show 60% of the decline in cognitive function relative to untreated individuals, or 2.2 points higher i.e., will show 40% of the decline in cognitive function relative to untreated individuals, when treated for the same specified period of time.
- the dosage is provided as a pharmaceutical composition that is composed of R-flurbiprofen, a pharmaceutically acceptable salt, a release agent, and additional optional ingredients.
- the dosage is provided as a pharmaceutical composition that is a tablet composed of R-flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
- the dosage is provided as a pharmaceutical composition that is a capsule is composed of R-flurbiprofen, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate, all encapsulated in lactose monohydrate, hydroxyl propyl methyl cellulose, titanium dioxide, tracetin/glycerol triacetate, and iron oxide.
- the present invention provides for the administration of R-flurbiprofen to an individual, for example, and individual having mild to moderate AD, so as to obtain a desired pharmacokinetic profile, for example, a desired concentration of R- flurbiprofen in the plasma over a period of time.
- a desired pharmacokinetic profile for example, a desired concentration of R- flurbiprofen in the plasma over a period of time.
- Such preferred pharmacokinetic profiles and/or endpoints may be achieved through the administration of specific doses, for example, 400 mg or 800 mg once or twice a day, or may be achieved through the administration of doses individually-tailored for the specific recipient, taking into account factors such as weight, percent body fat, metabolism, ingestion of NSAIDs, etc.
- the invention provides for a method of administering R-flurbiprofen to an individual, wherein said R-flurbiprofen is administered in an amount sufficient to result in a plasma C max of about 25 to about 150 ⁇ g per mL, and wherein said individual is known to have, or is suspected of having, AD.
- said plasma C max is from about 30 to about 95 ⁇ g per mL.
- said C max is from about 40 to about 80 ⁇ g per mL.
- said C max is between about 100 and about 600 ⁇ M.
- said plasma C max is from about 160 to about 380 ⁇ M.
- said C max is from about 170 to about 240 ⁇ M.
- said individual has mild to moderate AD.
- the invention provides for a method of administering R-flurbiprofen to an individual, wherein said R-flurbiprofen is administered in an amount sufficient to result in a cerebrospinal fluid C max of about 0.05 to about 7.5 ⁇ g per mL, and wherein said individual is known to have, or is suspected of having, AD.
- said C ma ⁇ s from about 0.08 to about 4.5 ⁇ g per mL.
- the invention provides for a method of administering R-flurbiprofen to an individual, wherein said R-flurbiprofen is administered in an amount sufficient to result in a cerebrospinal fluid C max of about 2 to 30 ⁇ M; from about 3.2 ⁇ M to about 20 ⁇ M; or from about 4 ⁇ M to about 12 ⁇ M.
- the time to achieve plasma C ma ⁇ will depend upon the individual to be treated, but is preferably between 0.75 to 3.75 hours.
- the t max time to C max
- the t max is from about 1.0 to 3.75 hours, or is from about 1.00 hour to about 3 hours, or is from about 1.00 to about 2.5 hours.
- t max is about 2 hours after administration.
- the t (half-life) is from about 3.75 to about 8.5 hours.
- C max cerebrospinal fluid
- Peak area of the m/z 243 ⁇ 199 flurbiprofen product ion is measured against the peak area of the m/z 246 ⁇ 202 flurbiprofen-D 3 internal standard product ion. Quantification may be performed using a weighted (1/x 2 ) linear least squares regression analysis for each enantiomer generated from fortified plasma standards prepared in bulk and frozen.
- the plasma half-life will also depend upon the individual to be treated. Preferably, the plasma half-life is from about 3.75 to about 8.5 hours.
- the invention provides a method of administering R-flurbiprofen to an individual having one or more indications of Alzheimer's disease, wherein said administration achieves a plasma concentration in said individual of R-flurbiprofen of between 30 and 95 ⁇ g per mL by no more than 3.75 hours after administration.
- said plasma concentration is achieved within 1.75 hours after administration.
- said plasma concentration is achieved between 0.75 hours and 3.75 hours after administration.
- said plasma concentration is between 50 and 80 ⁇ g per mL.
- said individual is an individual that has been diagnoses having mild to moderate Alzheimer's disease, or that would be diagnosed as having mild to moderate Alzheimer's disease according to a test of cognition.
- the invention provides a method of administering R-flurbiprofen to an individual in need of improvement in one more measures of cognition, comprising administering R-flurbiprofen orally and in a manner in which plasma levels of between 30 and 95 ⁇ g per mL are reached by 3.75 hours after administration. Further, the invention encompasses repeated dosing to achieve these levels for 1 week, two weeks, three weeks, four weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, one year, or preferably more than one year.
- the invention provides a method of treating an individual having, or suspected of having, Alzheimer's disease, comprising administering R-flurbiprofen in an amount sufficient to result in a C ma ⁇ of about 30 to about 95 ⁇ g per mL. In a more specific embodiment, said C max is between 40 and 80 ⁇ g per mL.
- the invention further provides a method of reducing a decline in a measure of cognitive function of an individual comprising administering R- flurbiprofen to said individual, wherein said administering results in the reduction of the decline in said measure of cognitive function as compared to a control.
- said control is the decline in said measure of cognitive function in an individual not given R-flurbiprofen, wherein said individual has or is suspected of having Alzheimer's disease.
- said control is the average decline in said measure of cognitive function in a plurality of individuals not given flurbiprofen, wherein said individuals have or are suspected of having Alzheimer's disease.
- said reduction in said decline in said measure of cognitive function is at least 25% compared to said control.
- said reduction in said decline in said measure of cognitive function is at least 40% compared to said control.
- said reduction in said decline in said measure of cognitive function is at least 60% compared to said control.
- said measure of cognitive function is an ADAS-cog test.
- said decline is 2.2 points in the ADAS-cog test over one year.
- said decline is 3.3 points in the ADAS-cog test over one year.
- said R-flurbiprofen is administered in a dose of about 400 mg twice daily.
- said R-flurbiprofen is administered in a dose of about 800 mg twice daily.
- the invention provides for a method of improving, or lessening a decline in, the progression of one or more disease markers of Alzheimer's disease in an individual having, or suspected of having, Alzheimer's disease, comprising administering R-flurbiprofen to said individual.
- said R-flurbiprofen is administered in an amount that achieves a C ma ⁇ of about 30 to about 95 ⁇ g per mL.
- said C ma ⁇ is between 40 and 80 ⁇ g per mL.
- said administration is continued at least once a day for at least four months. Jn another specific embodiment, said administration is continued at least once a day for at least eight months.
- said administration is continued at least once a day for at least twelve months.
- said disease marker is amyloid beta peptide (A ⁇ ), A 3 42 , or tau.
- said R-flurbiprofen is administered in a dose of about 400 mg twice daily.
- said R-flurbiprofen is administered in a dose of about 800 mg twice daily.
- the invention provides for a method of improving, or lessening a decline in, plaque pathology associated with Alzheimer's disease in an individual having, or suspected of having, Alzheimer's disease, comprising administering R-flurbiprofen to said individual.
- said administration of R-flurbiprofen achieves a C max of about 30 to about 95 ⁇ g per mL. In a more specific embodiment, said C max is between 40 and 80 ⁇ g per mL. In a specific embodiment, said administration is continued at least once a day for at least four months. In another specific embodiment, said administration is continued at least once a day for at least eight months. In another specific embodiment, said R- flurbiprofen is administered in a dose of about 400 mg per day. In another specific embodiment, said R-flurbiprofen is administered in a dose of about 800 mg per day.
- the invention provides for a method of administering R-flurbiprofen to an individual, wherein said R-flurbiprofen is administered in an amount sufficient to result in a plasma C max of about 35 to about 50 ⁇ g per mL, and wherein said individual is known to have, or is suspected of having, AD.
- said plasma C max is from about 38 to about 48 ⁇ g per mL.
- said C max is from about 39 to about 46 ⁇ g per mL.
- the invention provides for a method of administering R- flurbiprofen to an individual, wherein said R-flurbiprofen is administered in an amount sufficient to result in a plasma C max of about 45 to about 58 ⁇ g per mL, and wherein said individual is known to have, or is suspected of having, AD.
- said plasma C max is from about 47 to about 56 ⁇ g per mL.
- said plasma C max s from about 48 to about 55 ⁇ g per mL.
- said individual has mild to moderate AD.
- said individual has MCI.
- the time to achieve plasma C max will depend upon the individual to be treated, but is preferably between 0.75 to 2.25 hours.
- the t max (time to C ma ⁇ ) is from about 1.0 to 2.1 hours, or is from about 1.25 hour to about 2 hours, or is from about 1.00 to about 2.5 hours.
- the ty 2 (half-life) is from about 6.00 to about 10.0 hours; more preferably from about 6.5 to about 9.5 hours; and more preferably from about 7 to about 9 hours.
- the AUC area under the curve; total drug exposure
- the AUC is from about 350 (hr*ug/mL) to 750 (hr*ug/mL); is from about 400 (hr*ug/mL) to 650 (hr*ug/mL); or is from about 450 (hr*ug/mL) to 700 (hr*ug/mL).
- said individual has mild to moderate AD.
- said individual has MCI.
- the time to achieve plasma C ma ⁇ will depend upon the individual to be treated, but is preferably between 0.25 to 2.00 hours.
- the t max time to Cm x
- the t ⁇ /2 half-life
- the t ⁇ /2 half-life is from about 3.5 to about 8.5 hours; more preferably from about 4.0 to about 8.0 hours; and more preferably from about 4.8 to about 7.5 hours.
- the AUC area under the curve; total drug exposure
- the AUC is from about 250 (hr*ug/mL) to 700 (hr*ug/mL); is from about 300 (hr*ug/mL) to 650 (hr*ug/mL); or is from about 350 (hr*ug/mL) to 600 (hr*ug/mL).
- said individual has mild to moderate AD.
- said individual has MCI.
- the invention provides a method of treating Alzheimer's disease comprising administering to a patient in need of such treatment, a dose of a pharmaceutical composition comprising an effective amount of R-flurbiprofen and one or more pharmaceutically acceptable excipients, wherein a dose of an effective amount upon oral administration to a fasting subject provides a C ma ⁇ of about 30-95 ⁇ g per mL per dose.
- Oral administration of a dose, twice daily for at least 4 months, more preferably 8 months, and more preferably 1 year, provides an improvement or lessening in decline in cognitive function, biochemical disease marker progression, and/or plaque pathology.
- the dose can be provided twice daily, in a single or multiple dosage units (i.e., tablets or capsules) where the dose is about 350 mg R- flurbiprofen, 400 mg R-flurbiprofen, 450 mg R-flurbiprofen, 500 mg R-flurbiprofen, 550 mg R-flurbiprofen, 600 mg R-flurbiprofen, 650 mg R-flurbiprofen, 700 mg R- flurbiprofen, 750 mg R-flurbiprofen, 800 mg R-flurbiprofen, or 850 mg R- flurbiprofen.
- the dose is 400 mg; thus, a preferred method uses a composition of the invention comprising 400 mg R-flurbiprofen and a carrier or vehicle suitable for oral administration, e.g., in tablets or capsules.
- Another preferred dose is 800 mg of R-flurbiprofen, and a preferred method uses a composition of the invention comprising 400 mg R-flurbiprofen and a carrier or vehicle suitable for oral administration, e.g., in tablets or capsules.
- the invention provides a low dose based treatment regimen wherein the dose has about 200 mg R-flurbiprofen.
- the composition is substantially free of the (S)-stereoisomer of flurbiprofen.
- the invention provides a method of preventing the onset of Alzheimer's disease comprising administering to a patient, in need of such treatment, a pharmaceutical composition comprising an effective amount of R- flurbiprofen and one or more pharmaceutically acceptable excipients, wherein a single dose of an effective amount upon oral administration to a fasting subject provides a C max of about 30-95 ⁇ g per mL per dosage unit and wherein upon oral administration of a dosage unit, twice daily for at least 4 months, more preferably 8 months, and more preferably 1 year, provides an improvement or lessening of in decline in cognitive function, biochemical disease marker progression, and/or plaque pathology.
- administration of a dose to a fasting subject provides an AUC (area under curve of concentration versus time; total drug exposure) of from about 200 hr # ⁇ g/mL to about 600 hr » ⁇ g/mL.
- AUC area under curve of concentration versus time; total drug exposure
- t max time to C max
- ty 2 half-life
- the dose can be provided twice daily, in a single or multiple dosage units (i.e., tablets or capsules) where the dose is about 350 mg R-flurbiprofen, 400 mg R-flurbiprofen, 450 mg R-flurbiprofen, 500 mg R-flurbiprofen, 550 mg R-flurbiprofen, 600 mg R- flurbiprofen, 650 mg R-flurbiprofen, 700 mg R-flurbiprofen, 750 mg R-flurbiprofen, 800 mg R-flurbiprofen, or 850 mg R-flurbiprofen.
- the dose is 400 mg; thus, a preferred method uses a composition of the invention comprising 400 mg R- flurbiprofen and a carrier or vehicle suitable for oral administration, e.g., in tablets or capsules.
- Another preferred dose is 800 mg of R-flurbiprofen, and a preferred method uses a composition of the invention comprising 400 mg R-flurbiprofen and a carrier or vehicle suitable for oral administration, e.g., in tablets or capsules.
- the invention provides a low dose based prevention regimen wherein the dose has about 200 mg R-flurbiprofen.
- the composition is substantially free of the (S)-stereoisomer of flurbiprofen.
- the invention provides a method of decelerating the onset of Alzheimer's disease comprising administering to a patient in need of such treatment a pharmaceutical dosage having an effective amount of R-flurbiprofen and one or more pharmaceutically acceptable excipients, wherein a single dose of an effective amount upon oral administration to a fasting subject provides a C max of about 40-95 ⁇ g per mL per dose and wherein upon oral administration of a dose, twice daily for at least 4 months, preferably 8 months, and more desirably 1 year, provides an improvement or lessening of decline in cognitive function, biochemical disease marker progression, and/or plaque pathology.
- administration of a single dose to a fasting subject provides an AUC (area under curve of concentration versus time; total drug exposure) of from about 200 hr» ⁇ g/mL to about 600 hr* ⁇ g/mL.
- AUC area under curve of concentration versus time; total drug exposure
- t max time to C ma ⁇
- t ⁇ /2 half-life
- the dose can be provided twice daily, in a single or multiple dosage units (i.e., tablets or capsules) where the dose has about 350 mg R-flurbiprofen, 400 mg R-flurbiprofen, 450 mg R-flurbiprofen, 500 mg R-flurbiprofen, 550 mg R-flurbiprofen, 600 mg R-flurbiprofen, 650 mg R- flurbiprofen, 700 mg R-flurbiprofen, 750 mg R-flurbiprofen, 800 mg R-flurbiprofen, or 850 mg R-flurbiprofen.
- the dose is 400 mg; thus, a preferred method uses a composition of the invention comprising 400 mg R-flurbiprofen and a carrier or vehicle suitable for oral administration, e.g., in tablets or capsules.
- Another preferred dose is 800 mg of R-flurbiprofen, and a preferred method uses a composition of the invention comprising 400 mg R-flurbiprofen and a carrier or vehicle suitable for oral administration, e.g., in tablets or capsules.
- the invention provides a low dose based prevention regimen wherein the dose has about 200 mg R-flurbiprofen.
- the composition is substantially free of the (S)- stereoisomer of flurbiprofen.
- the compounds of the invention, and dosage forms of the invention, described herein, may be administered once, twice, three times, four times or more per day.
- tablets give an unexpectedly improved pharmacokinetic profile over capsules having the same amount of R-flurbiprofen. It was discovered that the C max was lower for tablets and the peak was broader giving an improved delivery of drug for treating Alzheimer's disease as compared to capsule dosage forms.
- the pharmacokinetic parameters referred to herein are based on the averages for a group of about 12 individuals for each dosing regimen (12 individuals treated with 200 mg BID, 12 individuals treated with 400 mg BID, 12 individuals treated with 800 mg BID, and 12 individuals treated with placebo).
- individuals will vary and can have pharmacokinetic parameters outside the given ranges.
- efficacy or therapeutic endpoint parameters are based on averages for a group of individuals and individuals experience efficacies that fall outside the given ranges.
- the invention in another embodiment, relates to a method for improving cognitive function. More particularly, this embodiment of the invention provides a method for improving cognitive function in individuals experiencing cognitive decline such as that experienced by Alzheimer's disease patients or those with mild cognitive impairment (MCI).
- MCI mild cognitive impairment
- the invention is based on the discovery that Alzheimer's disease patients that have experienced cognitive decline as a result of the disease can experience an improvement in cognition when administered a cognition improving effective amount of a pharmaceutical composition having R-flurbiprofen as the active ingredient.
- the invention provides a method for improving cognitive function in individuals experiencing cognitive decline.
- an individual in need of or desiring treatment is administered a composition having R-flurbiprofen in an amount of about 100 mg to about 1800 mg per day for at least 4 weeks, preferably at least 4 months, and more preferably at least 6 months.
- the amount of R- flurbiprofen administered to the individual is from about 200 to 1800 mg per day, more preferably the amount is from about 350 to 1650 mg per day.
- the composition used in the invention is formulated with one or more pharmaceutically acceptable excipients, salts, or carriers.
- the pharmaceutical composition can be delivered orally, preferably in a tablet or capsule dosage form.
- Oral administration of a single dose of the cognition improving effective amount of R-flurbiprofen to a fasting subject provides a C ma ⁇ of about 30-95 ⁇ g per mL.
- Oral administration of the R- flurbiprofen composition twice daily (b.i.d) for at least 4 weeks, preferably at least 4 months, even more preferably at least 6 months, and more desirably at least 1 year, provides an improvement in cognitive function as characterized by cognition tests. It is preferred that the improvement in cognitive function is statistically significant as compared to individuals treated with placebo.
- an individual treated with placebo having probable mild-to-moderate Alzheimer's disease is expected to score approximately 5.5 points lower on the ADAS-cog test after a specified period of time of treatment (e.g., 1 year) whereas an individual (having mild to moderate Alzheimer's disease) treated with the R-flurbiprofen composition for the same period of time will score no higher on the ADAS-cog scale or will have a better, i.e. lower, score (e.g., 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, or 4.0 or more points better).
- the oral dose is provided in capsule or tablet form.
- the dosage is provided as a pharmaceutical composition composed of R-flurbiprofen, a pharmaceutically acceptable salt, a release agent, and optionally additional ingredients.
- the invention in another embodiment of the invention, relates to a method for improving performance on cognitive tests. More particularly, this embodiment of the invention provides a method for improving performance on the ADAS-cog test in individuals who have experienced cognitive decline such as that experienced by Alzheimer's disease patients or those with mild cognitive impairment.
- the invention is based on the discovery that individuals that have experienced cognitive decline as a result of a disease or condition such as Alzheimer's disease or mild cognitive impairment can improvement their performance on the ADAS-cog test when administered a cognition improving effective amount of a pharmaceutical composition having R-flurbiprofen as the active ingredient. According to this method, an individual in need of or desiring treatment is identified and given the ADAS-cog test.
- the individual is then treated with a composition having R- flurbiprofen in an amount of about 100 mg to about 1800 mg per day for at least 4 weeks, preferably at least 4 months, and more preferably at least 6 months.
- the amount of R-flurbiprofen administered to the individual is from about 200 to 1800 mg per day, more preferably the amount is from about 350 to 1650 mg per day.
- An individual who is treated according to this method is then given the ADAS-cog test and the individual is expected to improve performance on the test. By improving performance, it is meant that a group of individuals that underwent the treatment will score the same or better (i.e., lower), in a statistically significant manner, on the ADAS-cog test.
- the improvement is 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0 or more points better (i.e., lower) on the ADAS-cog test.
- the composition used in the invention is formulated with one or more pharmaceutically acceptable excipients, salts, or carriers.
- the pharmaceutical composition can be delivered orally, preferably in a tablet or capsule dosage form. Oral administration of a single dose of the cognition improving effective amount of R-flurbiprofen to a fasting subject provides a C ma ⁇ of about 30-95 ⁇ g per mL.
- Oral administration of the R-flurbiprofen composition twice daily (b.i.d) for at least 4 weeks, preferably at least 4 months, even more preferably at least 6 months, and more desirably at least 1 year, provides an improvement in performance on the ADAS-cog test. It is preferred that the improvement in performance on the ADAS-cog test is statistically significant as compared to individuals treated with placebo.
- an individual treated with placebo having probable mild-to-moderate Alzheimer's disease is expected to score approximately 5.5 points higher on the ADAS-cog test after a specified period of time of treatment (e.g., 1 year) whereas an individual (having mild to moderate Alzheimer's disease) treated with the R-flurbiprofen composition for the same period of time will score no higher on the ADAS-cog scale or will have a better, i.e. lower, score (e.g., 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, or 4.0 or more points better).
- the oral dose is provided in capsule or tablet form.
- the dosage is provided as a pharmaceutical composition composed of R-flurbiprofen, a pharmaceutically acceptable salt, a release agent, and optionally additional ingredients.
- the pharmaceutical compositions and dosages of the present invention may be administered in any pharmaceutically-acceptable manner; however, tablet and capsule forms are preferred.
- tablets give an unexpectedly improved pharmacokinetic profile over capsules having the same amount of R-flurbiprofen. This is because the C max is lower for tablets and the peak is broader giving an improved delivery of drug for treating Alzheimer's disease as compared to capsule dosage forms.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- dosage unit form When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil.
- dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
- Soft gelatin capsules can be prepared in which capsules contain a mixture of the active ingredient and vegetable oil or non-aqueous, water miscible materials such as, for example, polyethylene glycol and the like.
- Hard gelatin capsules may contain granules of the active ingredient in combination with a solid, pulverulent carrier, such as, for example, lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives, or gelatin.
- Tablets are the preferred dosage form because of the improved pharmacokinetic profile as compared with other dosage forms (see above), and because of advantages afforded both to the patient (e.g., accuracy of dosage, compactness, portability, blandness of taste as well as ease of administration) and to the manufacturer (e.g., simplicity and economy of preparation, stability as well as convenience in packaging, shipping and dispensing). Tablets are solid pharmaceutical dosage forms containing therapeutic drug substances with or without suitable additives.
- Tablets are typically made by molding, by compression or by generally accepted tablet forming methods. Accordingly, compressed tablets are usually prepared by large-scale production methods while molded tablets often involve small- scale operations.
- Various tablet formulations may be made in accordance with the present invention. These include tablet dosage forms such as sugar-coated tablets, film- coated tablets, enteric-coated tablets, multiple-compressed tablets, prolonged action tablets and the like.
- Sugar-coated tablets SCT are compressed tablets containing a sugar coating. Such coatings may be colored and are beneficial in covering up drug substances possessing objectionable tastes or odors and in protecting materials sensitive to oxidation.
- Film-coated tablets (FCT) are compressed tablets that are covered with a thin layer or film of a water-soluble material. A number of polymeric substances with film-forming properties may be used. The film coating imparts the same general characteristics as sugar coating with the added advantage of a greatly reduced time period required for the coating operation.
- Enteric-coated tablets are also suitable for use in the present invention.
- Enteric-coated tablets are compressed tablets coated with substances that resist dissolution in gastric fluid but disintegrate in the intestine.
- Enteric coating can be used for tablets containing drug substances that are inactivated or destroyed in the stomach, for those which irritate the mucosa or as a means of delayed release of the medication.
- MCT Multiple compressed tablets
- layered tablets are prepared by compressing additional tablet granulation on a previously compressed granulation. The operation may be repeated to produce multilayered tablets of two, three or more layers.
- special tablet presses are required to make layered tablets. See, for example, U.S. Pat. No. 5,213,738, incorporated herein in its entirety by reference thereto.
- Press coated tablets are another form of multiple compressed tablets. Such tablets, also referred to as dry-coated tablets, are prepared by feeding previously compressed tablets into a tableting machine and compressing another granulation layer around the preformed tablets. These tablets have all the advantages of compressed tablets, i.e., slotting, monogramming, speed of disintegration, etc., while retaining the attributes of sugar coated tablets in masking the taste of the drug substance in the core tablet. Press-coated tablets can also be used to separate incompatible drug substances. Further, they can be used to provide an enteric coating to the core tablets. Both types of tablets (i.e., layered tablets and press-coated tablets) may be used, for example, in the design of prolonged-action dosage forms of the present invention.
- compositions or unit dosage forms of the present invention in the form of prolonged-action tablets may comprise compressed tablets formulated to release the drug substance in a manner to provide medication over a period of time.
- tablet types that include delayed-action tablets in which the release of the drug substance is prevented for an interval of time after administration or until certain physiological conditions exist.
- Repeat action tablets may be formed that periodically release a complete dose of the drug substance to the gastrointestinal fluids.
- extended release tablets that continuously release increments of the contained drug substance to the gastrointestinal fluids may be formed.
- optically pure R(-)-flurbiprofen can be combined as the active ingredient in intimate admixture with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques.
- the pharmaceutically acceptable carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral, parenteral (including intravenous, subcutaneous, intrathecal, and intramuscular), transdermal, and topical.
- parenteral including intravenous, subcutaneous, intrathecal, and intramuscular
- transdermal and topical.
- any of the usual pharmaceutical media or excipients may be employed.
- oral liquid preparations such as suspensions, elixirs and solutions; or aerosols; or excipients such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, capsules, caplets, and tablets.
- Solid oral preparations are generally preferred over liquid ones. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical pharmaceutically acceptable excipients are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Preferred solid oral preparations are tablets and capsules.
- compositions comprising optically pure R(-)-flurbiprofen, or pharmaceutically acceptable salts, solvates, or clathrates thereof.
- Acceptable stabilizers include, but are not limited to, L-cysteine hydrochloride, glycine hydrochloride, malic acid, sodium metabisulfite, citric acid, tartaric acid, and L-cystine dihydrochloride. See, e.g., U.S. Patent Nos.: 5,731,000; 5,763,493; 5,541,231; and 5,358,970, all of which are incorporated herein by reference.
- the active ingredient i.e., optically pure R-flurbiprofen
- controlled release means and/or delivery devices capable of releasing the active ingredient at a rate required to maintain constant pharmacological activity for a desirable period of time.
- Such dosage forms provide a supply of a drug to the body during a predetermined period of time and thus maintain drug levels in the therapeutic range for longer periods of time than conventional non-controlled formulations. Examples of controlled release pharmaceutical compositions and delivery devices which may be adapted for the adminisfration of the active ingredient of the invention are described in U.S.
- compositions of the invention suitable for oral administration may be presented as discrete units such as capsules, cachets, caplets, or tablets or aerosol sprays, each containing a predetermined amount of the active ingredient as a powder, as granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
- Such compositions may be prepared by any of the methods of pharmacy which include the step of bringing into association the active ingredient with a pharmaceutically acceptable carrier which constitutes one or more necessary ingredients.
- compositions are prepared by uniformly and intimately admixing the active ingredient with a liquid pharmaceutically acceptable carrier or a finely divided solid pharmaceutically acceptable carrier, or both, and then, if necessary, shaping the product into the desired presentation.
- a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, disintegrating agent, and/or surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the dosage form of R-flurbiprofen for example, 400 mg or 800 mg, can be compounded with any other compound determined to be suitable for the treatment of Alzheimer's disease.
- the dose of R-flurbiprofen may be compounded with an acetylcholinesterase (AChE) inhibitor.
- ACHE inhibitors useful for the treatment of Alzheimer's disease include, without limitation, Galanthamine (galantamine, Reminyl); E2020 (Donepezil, Aricept); Physostigmine; Tacrine (tetrahydroaminoacridine, THA); Rivastigmine; Phenserine; Metrifonate (Promem); or Huperazine.
- the dose of R-flurbiprofen may also be compounded with one or more pharmaceutically-acceptable antioxidants, for example, vitamin C (for example, 500-1000 mg per dose of R-flurbiprofen) and/or vitamin E (for example, 400-800 IU per dose of R-flurbiprofen).
- vitamin C for example, 500-1000 mg per dose of R-flurbiprofen
- vitamin E for example, 400-800 IU per dose of R-flurbiprofen.
- Flurbiprofen useful in making the pharmaceutical compositions and formulations of the present invention, and in useful in performing the methods of the present invention, may be made by any known method that produces optically-pure R-flurbiprofen.
- R-flurbiprofen is commercially available from, e.g., Sepracor Inc., (Marlborough, MA).
- racemic mixtures of flurbiprofen are available from a number of commercial sources including, e.g., Sigma (St. Louis, MO).
- the optically pure R-isomer flurbiprofen (or a desired enantiomeric excess of R-flurbiprofen) can then be obtained by resolving the racemic mixtures according to well-known methods.
- R-flurbiprofen compositions are disclosed in, e.g., US patent 5,200,198 to Geisslinger et al.
- the tablets are prepared using art known procedures.
- Active ulcer disease diagnosed in past 12 months includes patients who are taking medications for upper gastrointestinal protection on a regular (daily) basis, including proton pump inhibitors, H-2 receptor antagonists, and cytoprotective agents.
- the following drugs are examples: rabeprazole/Aciphex ® , omeprazole/Prilosec ® /Nexium ® , pantoprozole/Protonix ® , lansoprozole/Prevacid ® (proton pump inhibitors); cimetidine/Tagamet ® , ranitidine/Zantac ® , famotidine/Pepcid ® (H-2 receptor antagonists), misoprostol/Cytotec ® , sucralfate/Carafate ® (cytoprotective agents).
- Contraindications to lumbar puncture anticoagulant treatment, major structural abnormality or infection in the area of the lumbosacral spine, hypersensitivity to lidocaine).
- HTV human immunodeficiency virus
- Anticoagulant therapy such as warfarin within 12 weeks prior to randomization.
- Previous participation in this study. Treatment with any CYP2C9 inhibitor within a 2 week period prior to randomization.
- CYP2C9 inhibitors are examples of CYP2C9 inhibitors: amiodarone/Cordarone ® , fluconazole/Diflucan ® , fluvastatin/Lescol ® , fluvoxamine/Luvox ® , isoniazid/TNH ® , lovastatin/Mevacor ® , miconazole, paroxetine/Paxil ® , phenylbutazone, probenicid/Benemid ® , sertraline/Zoloft ® , sulfamethoxazole/Gantanol ® , sulfaphenazole, teniposide/Vumon ® , trimethoprim/Bactrim ® , zafirlukast/Accolate ® ; danshen (Salvia miltiorrhiza); Lycium barbarum.
- Treatment Procedures Drug Dosage, Administration, and Schedule [0111] The drug dosage and administration schedule is summarized in the table below. Subjects are instructed to take 1 capsule from Bottle A and 1 capsule from Bottle B 2 times per day (BID) for 20 days; Bottles A and B may contain R- flurbiprofen or placebo. The infraday dosing interval is approximately 12 hours, and the study drug is taken at approximately the same time each day. After 20 days (i.e., on Study Day 21), study participants undergo a pharmacokinetic study, as described below. Daily doses for the 4 groups of the study are:
- a complete physical examination is performed by a medically qualified professional at Screening, on Study Day 21, and at the 30-Day follow-up Nisit.
- a review of all major body systems is performed, including skin, head/ears/eyes/nose/throat (HEE ⁇ T), respiratory, cardiovascular, gastrointestinal, endocrine/metabolic, genitourinary, neurological, blood/lymphatic, and musculoskeletal.
- a fecal specimen is collected by rectal examination at Screening and on Study Day 21 and tested for the presence of occult blood. The rectal exam is included at the 30 Day Folio w-Up Nisit only if fecal occult blood was detected in the sample collected on Study Day 21.
- Assessments of height (height will be measured only at Screening visit), weight, and vital signs (systolic and diastolic blood pressure, pulse, temperature, and respirations) are included.
- a brief physical examination will be performed by a medically qualified professional at Study Day 1.
- a review of body systems will be assessed, as appropriate, evaluating and documenting any changes from the previous visit. Any clinically significant changes will be followed up per standards of good medical practice. The evaluation of previous and new adverse events is to be documented. Other body systems will be assessed as appropriate. All brief physical examination data will be recorded on the appropriate CRF.
- Electrocardiogram A standard 12-lead resting electrocardiogram (ECG) is performed at the Screening Nisit, Study Day 1, approximately 2-3 hours after administration of the first dose of study drug; Study Day 21, approximately 2-3 hours after administration of the last dose of study drug; End of Study 30-Day Follow-up Nisit, or as clinically indicated during the study.
- ECG 12-lead resting electrocardiogram
- Blood and urine samples are collected on Study Day 21 from fasted participants for clinical chemistries, hematology, coagulation parameters, and urinalysis. Blood samples are collected on Study Day 21 at 0.5, 1, 2, 4, and 6 hours, and, if possible, 8 and 24 hours, after adminisfration of the final dose of study drug.
- the total amount of blood collected for the pharmacokinetic analyses is approximately 64 mL. All blood samples for PK/PD analysis are analyzed for both R-flurbiprofen and S-flurbiprofen, and the extent of bioinversion of R-flurbiprofen to S-flurbiprofen is assessed.
- CSF levels of A ⁇ 40 and A ⁇ 42 are measured by a sandwich enzyme linked immunosorbent assay (ELISA) with increased sensitivity for low levels of A ⁇ .
- ELISA sandwich enzyme linked immunosorbent assay
- the Mini-Mental State Examination is administered to the subject at screening.
- the MMSE briefly evaluates orientation, memory, attention and calculation, language (naming, comprehension, repetition, writing), and ability to copy 2 intersecting pentagons.
- the maximum score is 30 points, with lower scores indicating more severe cognitive impairment.
- Subj ects who are interested in participating will provide information needed to assess eligibility criteria at this visit.
- Subjects who meet eligibility criteria provide signed informed consent to study personnel.
- the MMSE will be administered.
- Subjects' medical history is reviewed, including prescribed and over- the-counter medications and history of NSAID use for the preceding 60 days.
- Vital signs are recorded and a complete physical and neurological examination is conducted.
- a fecal specimen is collected by rectal examination and tested for the presence of occult blood.
- An ECG is obtained and blood and urine samples collected for clinical chemistries, hematology, coagulation parameters, and urinalysis.
- Study Day 1 scheduled within 30 days of the Screening Visit, is scheduled for the morning; subjects fast (no fluids or food) from midnight the night before.
- subjects On arrival at the clinic, subjects undergo a brief physical examination, and blood and urine samples are collected for clinical chemistries, hematology, coagulation parameters, and urinalysis.
- CSF is collected via lumbar puncture, and a blood sample is drawn and plasma prepared for A ⁇ measurements. As soon as possible after the lumbar puncture, subjects take their first dose of the study medication.
- a standard 12-lead resting electrocardiogram is performed approximately 2-3 hours after administration of the first dose of study drug, and an additional blood sample drawn 3 to 6 hours after administration of the first dose of study drug to analyze for evidence of bioinversion. Participants receive Telephone Visits on Study Days 7, 14 and 20 to verify compliance.
- Safety and tolerability endpoints include adverse events, vital signs, physical examinations, ECG, clinical laboratory tests (serum chemistry, hematology, and urinalysis, and fecal occult blood), and bioinversion of (R)- flurbiprofen to (S)- flurbiprofen. Bioinversion of R-flurbiprofen to (S)-flurbiprofen will be assessed by measurement of plasma concentrations of individuals (R)-enantiomers or (S)- enantiomers.
- endpoints are plasma pharmacokinetic parameters, CSF concenfration of R-flurbiprofen, and CSF and plasma A ⁇ concentration, including the amyloid species A/342, A ⁇ 40 and A ⁇ 38.
- Pharmacokinetics are assessed by measurement of plasma concentrations of R-flurbiprofen over time. Cerebrospinal fluid levels of R-flurbiprofen over time are assessed if possible, using the actual time of the CSF measurement and combining data from all subjects.
- the exploratory biomarkers beta amyloid fragments A/338, A ⁇ 40, and A/342 are measured in plasma and in CSF before and after 21 days administration of different dose levels of R- flurbiprofen.
- Baseline levels of biomarkers in CSF and plasma are used as covariates for analyzing treatment differences in final levels of biomarkers in CSF and plasma.
- Actual or estimated plasma or CSF levels of R-flurbiprofen are used as quantitative terms in predicting levels of biomarkers.
- Subj ect incidence rates of all adverse events will be tabulated by body system, preferred term, and severity. Tables and/or narratives of "on-study" deaths, serious and significant adverse events, including early withdrawals due to adverse events, will also be provided. Statistical analysis comparing the incidence rates between groups will be performed if there are sufficient numbers of events. [0127] Shift tables from the baseline visit to the end-of-study visit re presented for physical examination outcomes and all measured laboratory parameters. Change from baseline in quantitative laboratory parameters are compared between treatment groups. Descriptive statistics for vital signs and ECG parameters are provided for each visit and for the change from baseline. Treatment groups are compared for differences in change from baseline.
- the plasma concenfration time profile of R-flurbiprofen is analyzed using nonlinear modeling, and preliminary estimates of PK parameters are obtained. Estimates include individual and mean half-life, clearance, AUC, C ma ⁇ 5 T max , and average steady-state concentration. Cerebrospinal fluid levels of R-flurbiprofen are summarized. If plasma concentrations over time are similar to those found in other patient populations, Bayesian estimation is used to estimate population PK parameters, allowing the PK parameters observed in this population to be evaluated in the context of data observed in additional clinical studies. Estimates include the mean and individual PK parameters as well as the magnitude of intersubject variability.
- All study dosage forms (R-flurbiprofen 200-mg, 400-mg and placebo capsules) are filled into high density polyethylene bottles (HDPE) capped using child- resistant closures with induction inner seals. Bottles are packaged in kits containing 2 bottles (1 Bottle A and 1 Bottle B) that contain the doses required for 1 subject to complete Study Days 1 through 20. Regulatory and Ethical Obligations
- ADCS Alzheimer's Disease Cooperative Study
- This Example provides a randomized, double-blind, placebo-controlled study of the effect of daily treatment with R-flurbiprofen on measures of cognitive and global function in subjects with mild to moderate dementia of the Alzheimer's type.
- Study subj ects are diagnosed as having mild to moderate dementia of the Alzheimer's type, and have a Mini Mental State Examination score (MMSE) > 15 and ⁇ 26.
- Subjects may be taking acetylcholinesterase (AChE) inhibitors provided the dose has been stable for at least 3 months.
- Subjects will be stratified at randomization for use/non-use of AChE inhibitors.
- a target of 201 subjects (67 subjects per arm) in 3 treatment groups are enrolled for 12 Months with optional follow-on treatment after Month 12 (2 treatment groups).
- Subj ects in this study have mild to moderate dementia of the Alzheimer' s type and meet the entry criteria as follows.
- Subjects must have a reliable caregiver who can read, understand and speak English, accompany them to each clinic visit, and is willing to sign the caregiver Assent Form. Caregiver must either live with the subject or see them on at least 4 days per week, with contact sufficient to insure meaningful assessment of changes in subject behavior with time, and must be prepared to verify daily compliance with study medication. • Subjects taking antidepressant, antipsychotic, and/or anxiolytic drugs, vitamin E and/or Gingko biloba are eligible, provided that the dose has been stable for at least 3 months prior to randomization. • Adequate vision and hearing to participate in study assessments. Exclusion Criteria
- Anticoagulant therapy such as warfarin within 12 weeks prior to randomization.
- CYP2C9 inhibitors • Treatment with any CYP2C9 inhibitor within a 2 week period prior to randomization.
- the following drugs and herbal preparations are examples of CYP2C9 inhibitors: amiodarone, fluconazole, fluvoxamine, isoniazid, phenylbutazone, probenicid, sulfamethoxazole, sulfaphenazole, trimethoprim, zafirlukast; danshen (Salvia miltiorrhiza); Lycium barbarum.
- Treatment with the CYP2C9 substrates fluvastatin, tolbutamide, or glyburide (glibenclamide).
- Drug Dosage, Administration, and Schedule [0142] The drug dosage, adminisfration and schedule are summarized below. Subjects are instructed to take 1 tablet from Bottle A and 1 tablet from Bottle B 2 times per day. The infraday dosing interval is approximately 12 hours. Study drug should be taken at approximately the same time each day during the participation in this 12-month study. The total daily doses for the 3 arms of the study are:
- Concomitant Therapy [0143] Concomitant medications are assessed at all study visits. Concomitant medications are prescribed or over-the-counter medications and should be consistent with the inclusion/exclusion criteria. The potential for drug-drug interactions exists whenever 2 or more drugs are co-administered. In particular, flurbiprofen has been shown to inhibit the metabolism of drugs that are substrates of the enzyme cytochrome P450 (CYP) 2C9.
- CYP2C9 Inhibitors Concurrent use of CYP2C9 inhibitors (e.g., amiodarone, fluconazole, fluvoxamine, isoniazid, miconazole, phenylbutazone, probenicid, sulfamethoxazole, sulfaphenazole, teniposide, trimethoprim, zafirlukast; danshen [Saliva miltiorrhiza]; Lycium barbarum). • Ansaid®, Froben® or any other flurbiprofen-containing medication. • Other investigational medication or devices. • Cytotoxic chemotherapy. Study Procedures
- ADAS- cog Alzheimer's Disease Assessment Scale cognitive subscale
- the ADAS-cog is administered by a qualified professional to assess change in cognitive function. Administration takes place on Day 1, Month 3, Month 6, Month 9, Month 12 or Early Termination Prior to Month 12, Month 15, Month 18, Month 21, and Month 24 (or End of Study).
- CDR-sb The Clinical Dementia Rating-sum of boxes (CDR-sb) is a clinical scale that rates the severity of dementia as absent, questionable, mild, moderate or severe. The score is based on interviews with the subject and caregiver, using a structured interview to assess 6 domains: memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care. Training is conducted to standardize administration across sites. This instrument is administered by an experienced rater who also administers the CTBIC+ and who is uninvolved with other assessments of the subject. Adminisfration takes place on Day 1, Month 3, Month 6, Month 9, Month 12 or Early Termination Prior to Month 12, Month 15, Month 18, Month 21, and Month 24 (or End of Study).
- NPI Neuropsychiatric Inventory
- ADCS-ADL Alzheimer's Disease Cooperative Study- Activities of Daily Living
- This instrument includes items to assess activities from traditional scales (grooming, dressing, walking, bathing, feeding, toileting) as well as instrumental ADL scales (shopping, preparing meals, using household appliances, keeping appointments, reading). Administration will take place on Day 1, Month 6, and at Month 12 or Early Termination Prior to Month 12.
- the Clinician Interview Based Impression of Change plus caregiver input is an instrument to assess global function, based on an interview with the caregiver.
- the CIBIC+ will be administered by an experienced rater who also administers the CDR-sb and is uninvolved with other assessments of the subject. Adminisfration will take place on Day 1, Months 3, 6, 9 and at Month 12 or Early Termination Prior to Month 12. The Day 1 interview will be recorded on videotape for study purposes.
- MMSE Mini Mental State Examination
- AD studies evaluates orientation, memory, attention, concentration, naming, repetition, comprehension, the ability to create a sentence and to copy two intersecting polygons.
- the MMSE is conducted during screening to establish eligibility. It is administered at Month 6, Month 12 or Early Termination Prior to Month 12, Month 18, and Month 24 (or End of Study) to evaluate change in subject assessment.
- a complete physical examination is performed by a medically qualified professional at screening and at Month 12 or Early Termination Prior to Month 12, and Month 24 (or End of Study).
- Assessments of height is measured only at the Screening Visit
- weight and vital signs (systolic and diastolic blood pressure, pulse, temperature, and respirations) are included. All complete physical examination data will be recorded on the appropriate source documents.
- Electrocardiogram A standard 12-lead resting electrocardiogram (ECG) is performed at screening and at Month 12 or Early Termination Prior to Month 12, and Month 24 (or End of Study). It is preferred to have the Month 12 or Early Termination prior to Month 12 ECG conducted prior to venipuncture. The ECG readings and, if available, the computer analysis, will be reviewed locally by an Investigator. The ECG report is reviewed, signed, and dated by the Investigator. Patients with clinically significant ECG findings are referred for follow-up as deemed appropriate by the Investigator.
- Monthly Phone Visits [0155] Monthly phone conversations with the caregiver are conducted to assess possible AEs and compliance with study medication and visit schedules. The phone visits are conducted during Week 2, Months 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23 (see Appendix A, Schedule of Assessments).
- Vital Signs are assessed at each of the following visits: at Screening, Day 1, Month 1, Month 3, Month 6, Month 9, Month 12 or Early Termination Prior to Month 12, Month 15, Month 18, Month 21, Month 24 (or End of Study), and 30-Day Off-Drug Follow-up.
- Blood and urine samples for clinical laboratory analyses are collected at Screening, Day 1, Month 1, Month 3, Month 6, Month 9, Month 12 or Early Termination Prior to Month 12, Month 15, Month 18, Month 21, Month 24 (or End of Study), 30-Day Off-Drug Follow-up, and analyzed to determine whether a value is outside the laboratory's normal range, and if so, whether the deviation is clinically significant. If clinically significant, laboratory tests will be repeated according to good medical practice. Approximately 17 ml of blood is collected for clinical laboratory analyses at each visit.. An abnormal laboratory value will be reported as an AE only if it involves therapeutic medical intervention, if the Investigator considers it to be an AE, or if it leads to study discontinuation.
- the primary efficacy endpoints are the rate of change in the CDR-sb and the ADAS-cog, using a model based on slopes.
- the secondary efficacy endpoint is the score on the ADCS-ADL. Exploratory endpoints will be CIBIC+, MMSE and NPI.
- Safety endpoints include incidence of AEs, changes from baseline in physical examination and clinical laboratory test results. Additional endpoints are PK parameters based on measurements from blood samples taken throughout the study. [0164] Efficacy analyses for primary, secondary and exploratory endpoints include the baseline score as a covariate, and also a term for the stratification variable: use or non-use of AChE inhibitor at baseline.
- ITT Intent to Treat
- a Per Protocol analysis population will include all subjects in the ITT population who did not have any major protocol violations. Major protocol violations is determined prior to unblinding, based on observed data. All efficacy analyses are repeated for this population. Any differences in the efficacy results between the 2 analysis populations are investigated and explained.
- Demographic and other baseline characteristics are summarized for all subjects in both the ITT analysis population and the Per Protocol analysis population. Subject height, weight, and age is summarized and tabulated. Treatment groups are assessed statistically for similarity at baseline and results are compared between the ITT and Per Protocol analysis populations, and adjustments or subset analyses are performed if appropriate.
- the primary efficacy outcomes, CDR-sb and ADAS-cog, are analyzed by comparing the rates of change in CDR-sb and ADAS-cog between the 800 mg BID group and the placebo group.
- the type I error rate are adjusted appropriately for the interim analysis.
- the 400 mg BID group is compared to both the 800 mg BID group and the placebo group as secondary analyses using the same model and adjusting for multiple comparisons.
- Safety is assessed based on AE incidence, physical examinations, vital sign measurements, ECG measurements, clinical laboratory test results, and rates of bioinversion.
- the incidence of AEs is summarized by treatment group with counts and percentages.
- Descriptive statistics for vital sign and ECG measurements, by freatment and time (after dose) are provided.
- Plasma levels of R-flurbiprofen will be summarized by treatment group over time.
- All study dosage forms (R-flurbiprofen 400 mg and placebo tablets) are filled into high-density polyethylene bottles capped using child-resistant closures with induction sealed inner seals.
- Bottles are packaged in kits containing 6 bottles in each kit.
- Each kit (3 Bottles “A” and 3 Bottles “B") contain the doses required for 1 subject for a 3-month period.
- Each bottle in each kit is labeled with a 2-part 3-panel double-blind bottle label with detachable blinding panel that is removed immediately prior to dispensing the bottle to the subject.
- a new kit is dispensed to each subject every 3 months thereafter until the subject has completed 12 months of dosing.
- a total of 4 kits will be dispensed to each subject completing the full 12 months dosing period of the study. Labeling
- kits and the bottles contained therein are individually labeled with a unique and randomized kit number that exactly identify the contents of each bottle once the blinding is broken.
- the blinded portion of the label contains the identity of the dosage form and the manufacturer's production lot number.
- each bottle label includes a study medication expiry date and a detachable portion of the label (removed and attached to the CRF).
- the R-flurbiprofen can be administered twice daily as tablets containing 400 mg of active ingredient or as a capsule containing 400 mg of the active ingredient.
- a higher dose can be administered to the patient in need of such treatment which can involve the patient taking e.g., a 800 mg dose of R-flurbiprofen in the morning and a 800 mg dose of R-flurbiprofen in the evening.
- an individual is diagnosed by a doctor as having the disease using a suitable combination of observations.
- One criterion indicating a likelihood of mild-to-moderate Alzheimer's disease is a score of about 15 to about 26 on the MMSE test.
- R-flurbiprofen can also be administered in liquid or dosage forms.
- the dosages can also be divided or modified, and taken with or without food.
- the 400 mg dose can be divided into two 200 mg tablets or capsules.
- the NSATD i.e., R-flurbiprofen
- the NSATD can also be administered twice daily in liquid, capsule, or tablet dosage forms where the dose has various amounts of R-flurbiprofen (i.e., 850 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 450 mg, 350 mg, 300 mg, 250 mg, 200 mg, 150 mg, and 100 mg).
- the dosages can also be divided or modified, and taken with or without food.
- the doses can be taken during treatment with over medications for treating Alzheimer's disease or symptoms thereof.
- the NSATD can be administered in the morning as a tablet containing 400 mg of active ingredient (i.e., R-flurbiprofen) and an acetylcholine esterase inhibitor (i.e., tacrine (Cognex®), donepezil (Aricept®), rivastigmine (Exelon®), and galantamine (Reminyl®)), and/or an NMDA antagonist (i. e., memantine). It may be desirable to lower the amount of acetylcholine esterase inhibitor (and/or NMDA antagonist) and/or NSATD to avoid adverse side effects associated with higher doses of these compounds. Alternatively, the acetylcholine esterase inhibitor (and/or NMDA antagonist) and NSATD can be co- formulated into a single dosage form, i.e., liquid, tablet, capsule, etc.
- active ingredient i.e., R-flurbiprofen
- an acetylcholine esterase inhibitor i.
- EXAMPLE 8 PREVENTION OF ALZHEIMER'S DISEASE
- patients desiring prophylaxis against Alzheimer's disease can be treated with R-flurbiprofen.
- Those needing prophylaxis can be assessed by monitoring assayable disease markers, detection of genes conferring a predisposition to the disease, other risks factors such as age, diet, other disease conditions associated with Alzheimer's.
- the patient can also be treated with a combination of an NMDA antagonist (e.g., memantine) and R- flurbiprofen to delay or prevent the onset of Alzheimer's disease or symptoms thereof.
- an NMDA antagonist e.g., memantine
- the patient desiring prophylaxis against Alzheimer's disease or prophylaxis of a worsening of the symptoms of Alzheimer's disease can be treated with R-flurbiprofen in an amount sufficient to delay the onset or progression of symptoms of Alzheimer's disease.
- a patient can be treated with 800 mg of NSATD (i.e., R-flurbiprofen) twice daily.
- Another preventive regimen involves administering to the patient 400 mg of R-flurbiprofen twice daily.
- R-flurbiprofen twice daily can be administered to reduce sides-effects associated with the use of higher levels of the active ingredient.
- the preventive treatment can also be, e.g., treatment on alternating days with R-flurbiprofen, or alternating weeks.
- Other preventive freatment regimens include, but are not limited to, treatment with R-flurbiprofen for 3 weeks out of every 4 weeks, or for several months followed by no treatment for a month and then treatment for several months in an alternating on off schedule to reduce side-effects or toxicity problems.
- R-flurbiprofen doses of about 400 mg to 800 mg can decelerate or delay the onset of Alzheimer's disease or prevent the occurrence of Alzheimer's disease. It can be advantageous to utilize a low dosage prevention regimen which involves administration of pharmaceutical doses of 200 mg R-flurbiprofen twice daily.
- C(T) concentration at time T
- D dose
- N volume
- N_F volume of distribution over systemic availability
- KOI absorption rate constant
- K10 elimination rate constant
- CL_F clearance over systemic availability
- T time.
- K10_HL is the terminal half-life and as the skilled artisan recognizes, all T ⁇ / 2 values disclosed herein are K10_HL.
- Results of the pharmacokinetic study for the 200 BTD, 400 BTD and 800 BTD groups is shown in FIG. 2. Predicted results are shown in the table below.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004311577A AU2004311577A1 (en) | 2003-07-11 | 2004-07-12 | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
JP2006518971A JP2007528857A (en) | 2003-07-11 | 2004-07-12 | Pharmaceutical methods, dosing regimens and dosage forms for the treatment of Alzheimer's disease |
CA002532207A CA2532207A1 (en) | 2003-07-11 | 2004-07-12 | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
EP04821024A EP1651195A4 (en) | 2003-07-11 | 2004-07-12 | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48676903P | 2003-07-11 | 2003-07-11 | |
US60/486,769 | 2003-07-11 | ||
US51766603P | 2003-11-05 | 2003-11-05 | |
US60/517,666 | 2003-11-05 | ||
US56068504P | 2004-04-07 | 2004-04-07 | |
US60/560,685 | 2004-04-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005065069A2 true WO2005065069A2 (en) | 2005-07-21 |
WO2005065069A3 WO2005065069A3 (en) | 2005-09-22 |
Family
ID=34753665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/022339 WO2005065069A2 (en) | 2003-07-11 | 2004-07-12 | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
Country Status (7)
Country | Link |
---|---|
US (5) | US20050042284A1 (en) |
EP (1) | EP1651195A4 (en) |
JP (2) | JP2007528857A (en) |
KR (1) | KR20060040676A (en) |
AU (1) | AU2004311577A1 (en) |
CA (1) | CA2532207A1 (en) |
WO (1) | WO2005065069A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
JP2007106732A (en) * | 2005-10-14 | 2007-04-26 | Ortec Inc | Method and composition for altering cell function |
EP2111868A1 (en) | 2007-10-26 | 2009-10-28 | Grifols, S.A. | Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders |
EP2468270A1 (en) | 2010-12-21 | 2012-06-27 | GALENpharma GmbH | (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases |
US8865763B2 (en) | 2005-10-14 | 2014-10-21 | Alltech, Inc. | Methods and compositions for altering cell function |
US8871715B2 (en) | 2005-10-14 | 2014-10-28 | Alltech, Inc. | Use of selenium compounds, especially selenium yeasts for altering cognitive function |
US9723346B2 (en) | 2011-07-06 | 2017-08-01 | Symphony Advanced Media | Media content synchronized advertising platform apparatuses and systems |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060004086A1 (en) * | 2000-04-13 | 2006-01-05 | Mayo Foundation For Medical Education And Research | Method of reducing Abeta42 and treating diseases |
EP1284729A4 (en) * | 2000-04-13 | 2007-12-19 | Mayo Foundation | A(beta)42 lowering agents |
WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
CA2533896A1 (en) * | 2003-07-28 | 2005-02-10 | Mallinckrodt, Inc. | Improved stearate composition and method of production thereof |
US20050252144A1 (en) * | 2004-04-29 | 2005-11-17 | Macdonald Robert A | Veneers for walls, retaining walls and the like |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
BRPI0514303A (en) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | pharmaceutical composition and method for treating neurodegenerative disorders |
WO2007014124A2 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
EP2007385A4 (en) * | 2006-03-23 | 2010-08-18 | Sinai School Medicine | Cardiovascular composition and use the same for the treatment of alzheimers disease |
WO2008006099A2 (en) * | 2006-07-07 | 2008-01-10 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
WO2008095186A1 (en) * | 2007-02-01 | 2008-08-07 | Myriad Genetics, Inc. | Drug substance preparations, pharmaceutical compositions and dosage forms |
JP5209043B2 (en) * | 2007-05-07 | 2013-06-12 | メルク・シャープ・アンド・ドーム・コーポレーション | Gamma secretase regulator |
KR20100037053A (en) * | 2007-06-01 | 2010-04-08 | 쉐링 코포레이션 | Gamma secretase modulators |
AU2008263206A1 (en) * | 2007-06-01 | 2008-12-18 | Schering Corporation | Gamma secretase modulators |
CA2692253A1 (en) * | 2007-06-29 | 2009-01-08 | Schering Corporation | Gamma secretase modulators |
EP2185522A1 (en) * | 2007-08-06 | 2010-05-19 | Schering Corporation | Gamma secretase modulators |
MX2010002674A (en) * | 2007-09-06 | 2010-03-25 | Schering Corp | Gamma secretase modulators. |
AR068636A1 (en) * | 2007-09-28 | 2009-11-25 | Schering Corp | MODULATORS OF THE GAMMA SECRETASA |
US8450343B2 (en) * | 2007-12-06 | 2013-05-28 | Xianhai Huang | Gamma secretase modulators |
EP2227471A1 (en) * | 2007-12-11 | 2010-09-15 | Schering Corporation | Gamma secretase modulators |
MX2010006379A (en) * | 2007-12-11 | 2010-09-07 | Schering Corp | Gamma secretase modulators. |
RU2011123862A (en) | 2008-11-13 | 2012-12-20 | Шеринг Корпорейшн | GAMMA SECRETASE MODULATORS |
US8809318B2 (en) | 2008-11-13 | 2014-08-19 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
JP2012513400A (en) | 2008-12-22 | 2012-06-14 | シェーリング コーポレイション | γ-secretase modulator |
JP2012513399A (en) | 2008-12-22 | 2012-06-14 | シェーリング コーポレイション | γ-secretase modulator |
US20120245158A1 (en) | 2009-06-16 | 2012-09-27 | Xianhai Huang | Gamma secretase modulators |
EP2443121A2 (en) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gamma secretase modulators |
US20120232108A1 (en) | 2009-06-16 | 2012-09-13 | Xianhai Huang | Gamma secretase modulators |
GB2493914A (en) * | 2011-08-19 | 2013-02-27 | Univ Jw Goethe Frankfurt Main | Flurbiprofen and related compounds for the treatment of skin diseases |
CN104955453B (en) * | 2012-12-19 | 2018-09-18 | 原生质生物科学股份有限公司 | LFA-1 inhibitor formulations |
WO2017180807A1 (en) | 2016-04-15 | 2017-10-19 | Baxalta Incorporated | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1578650A (en) * | 1924-02-27 | 1926-03-30 | Remington Typewriter Co | Typewriting machine |
GB1091403A (en) * | 1964-01-24 | 1967-11-15 | Boots Pure Drug Co Ltd | Therapeutically active phenylalkane derivatives |
FR1546478A (en) * | 1967-01-27 | 1968-11-22 | Rhone Poulenc Sa | New derivatives of 3-benzoylphenylacetic acid and their preparation |
US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
NL7503310A (en) * | 1975-03-20 | 1976-09-22 | Philips Nv | CONNECTIONS WITH ANTIDEPRESSIVE ACTION. |
GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
US4089969A (en) * | 1976-07-14 | 1978-05-16 | Syntex (U.S.A.) Inc. | 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof |
US4209638A (en) * | 1977-03-08 | 1980-06-24 | The Boots Company Limited | Preparation of therapeutic agents |
US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4337273A (en) * | 1980-05-15 | 1982-06-29 | Thomas Jefferson University | Methods of increasing coronary blood flow through vasodilation by flurbiprofen |
MX7065E (en) * | 1980-06-06 | 1987-04-10 | Sankyo Co | A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4686237A (en) * | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) * | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
IL74497A (en) * | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
US4668794A (en) * | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
ATE68785T1 (en) * | 1985-07-31 | 1991-11-15 | Hoechst Ag | N-SUBSTITUTED 5-NITROANTHRANILIC ACIDS, PROCESSES FOR THEIR PRODUCTION, THEIR USE AND PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS. |
EP0223403B1 (en) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
JPH01501705A (en) * | 1986-01-30 | 1989-06-15 | ユニバ−シテイ・オブ・ユタ | Treatment of bone loss |
HU201906B (en) * | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
FI95572C (en) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
DE3824353A1 (en) * | 1988-07-19 | 1990-01-25 | Paz Arzneimittelentwicklung | METHOD FOR SEPARATING MIXED ENANTIOMER ARYLPROPIONIC ACIDS |
JPH0248526A (en) * | 1988-08-08 | 1990-02-19 | Sumitomo Pharmaceut Co Ltd | Indomethacin injection and production thereof |
US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
US5213738A (en) * | 1990-05-15 | 1993-05-25 | L. Perrigo Company | Method for making a capsule-shaped tablet |
US5015764A (en) * | 1990-06-18 | 1991-05-14 | Ethyl Corporation | Preparation of optically active aliphatic carboxylic acids |
DE4028906A1 (en) * | 1990-09-12 | 1992-03-19 | Paz Arzneimittelentwicklung | MEDICINAL PRODUCTS AND THEIR PREPARATION AND THEIR USE IN THE CONTROL OF PAIN AND / OR DEFENSE AND / OR FEVER OF ANIMALS AND PEOPLE |
US5177080A (en) * | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
DE69206306T2 (en) * | 1991-04-08 | 1996-06-13 | Sumitomo Chemical Co | Optically active secondary amine compound, process for producing an optically active secondary amine compound and process for producing optically active carboxylic acid by using this compound. |
US5192753A (en) * | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
US5235100A (en) * | 1992-01-24 | 1993-08-10 | Ethyl Corporation | Preparation of optically active aliphatic carboxylic acids |
US5331000A (en) * | 1992-03-09 | 1994-07-19 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen |
ATE179329T1 (en) * | 1992-06-30 | 1999-05-15 | Procter & Gamble Pharma | MEDICINAL PRODUCTS FOR THE TREATMENT OF ARTHRITIS THAT CONTAIN PHOSPHONATES AND NSAIDS |
IT1256450B (en) * | 1992-11-26 | 1995-12-05 | Soldato Piero Del | NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION |
ATE151740T1 (en) * | 1992-12-02 | 1997-05-15 | Knoll Ag | METHOD FOR PRODUCING ESSENTIAL ENANTIOMERS OF PHENYLPROPIONIC ACIDS |
US5380867A (en) * | 1992-12-02 | 1995-01-10 | Hoechst Celanese Corporation | Selective precipitation of α-aryl carboxylic acid salts |
US5382591A (en) * | 1992-12-17 | 1995-01-17 | Sepracor Inc. | Antipyretic and analgesic methods using optically pure R-ketorolac |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US5541231A (en) * | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
GB9315856D0 (en) * | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
US5574022A (en) * | 1994-04-14 | 1996-11-12 | The Center For Innovative Technology | Method of attenuating physical damage to the spinal cord |
US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
US6025395A (en) * | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug response by a serotonin 1A receptor antagonist |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5935860A (en) * | 1995-03-07 | 1999-08-10 | The George Washington University | Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia |
US5626838A (en) * | 1995-03-13 | 1997-05-06 | The Procter & Gamble Company | Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
US6160018A (en) * | 1995-03-13 | 2000-12-12 | Loma Linda University Medical Center | Prophylactic composition and method for alzheimer's Disease |
US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
US6245347B1 (en) * | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
US5750564A (en) * | 1995-09-12 | 1998-05-12 | Hellberg; Mark | Anti-oxidant esters of non-steroidal anti-inflammatory agents |
US5897880A (en) * | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
IT1277741B1 (en) * | 1995-12-28 | 1997-11-12 | Dompe Spa | PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING ALKYLAMMONIUM SALTS OF 2-ARYLPROPIONIC ACIDS |
SE9600070D0 (en) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
US6231888B1 (en) * | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
AU3641597A (en) * | 1996-06-21 | 1998-01-07 | Advanced Research And Technology Institute, Inc. | Methods and compositions comprising r-ibuprofen |
EP1006798A4 (en) * | 1996-09-05 | 2003-03-05 | Massachusetts Inst Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
US6184248B1 (en) * | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
HRP970485A2 (en) * | 1996-09-13 | 1998-08-31 | Joerg Rosenberg | Process for producing solid pharmaceutical forms |
US5898094A (en) * | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
US5858738A (en) * | 1996-11-07 | 1999-01-12 | Merck & Co., Inc. | Ermophilane sesquiterpenoids as HIV intergrase inhibitors |
ATE446748T1 (en) * | 1997-03-10 | 2009-11-15 | Univ Loma Linda Med | USE OF R-CARPROFEN TO PREVENT ALZHEIMER'S DISEASE |
GB9705989D0 (en) * | 1997-03-22 | 1997-05-07 | Boots Co Plc | Therapeutic composition |
GB9710521D0 (en) * | 1997-05-22 | 1997-07-16 | Boots Co Plc | Process |
US6365180B1 (en) * | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
IT1298214B1 (en) * | 1998-01-28 | 1999-12-20 | Dompe Spa | SALTS OF (R) 2- (3-BENZOYLFENYL) PROPIONIC ACID AND THEIR PHARMACEUTICAL COMPOSITIONS. |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
US6054451A (en) * | 1998-04-21 | 2000-04-25 | Algos Pharmaceutical Corporation | Analgesic composition and method for alleviating pain |
CA2342628C (en) * | 1998-09-03 | 2009-07-07 | Loma Linda University Medical Center | The use of r-flurbiprofen for the treatment of inflammation |
JP2002528495A (en) * | 1998-10-30 | 2002-09-03 | ニトロメド インコーポレーテッド | Nitrosated and nitrosylated non-steroidal anti-inflammatory compounds, compositions and methods of use |
IN189741B (en) * | 1998-11-09 | 2003-04-19 | Council Scient Ind Res | |
CA2350531A1 (en) * | 1998-11-13 | 2000-05-25 | Smriti Iyengar | Method for treating pain |
US6726929B1 (en) * | 1998-12-18 | 2004-04-27 | Basf Aktiengesellschaft | Pharmaceutical mixture comprising a profen |
DE19907895A1 (en) * | 1999-02-24 | 2000-11-16 | Paz Arzneimittelentwicklung | Use of R-arylpropionic acids for the production of medicaments for the treatment of diseases in humans and animals which can be influenced therapeutically by inhibiting the activation of NF-kB |
US6383527B1 (en) * | 1999-03-04 | 2002-05-07 | Nps Pharmaceuticals, Inc. | Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID |
ATE307808T1 (en) * | 1999-03-24 | 2005-11-15 | Scherer Technologies Inc R P | PHARMACEUTICAL FORMULATIONS WITH IMPROVED SOLUBILITY IN WATER |
US6372760B1 (en) * | 1999-03-31 | 2002-04-16 | Eisai Co., Ltd. | Stabilized composition comprising antidementia medicament |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6368618B1 (en) * | 1999-07-01 | 2002-04-09 | The University Of Georgia Research Foundation, Inc. | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
EP1284729A4 (en) * | 2000-04-13 | 2007-12-19 | Mayo Foundation | A(beta)42 lowering agents |
US20060004086A1 (en) * | 2000-04-13 | 2006-01-05 | Mayo Foundation For Medical Education And Research | Method of reducing Abeta42 and treating diseases |
US6355666B1 (en) * | 2000-06-23 | 2002-03-12 | Medinox, Inc. | Protected forms of pharmacologically active agents and uses therefor |
ATE366569T1 (en) * | 2000-07-20 | 2007-08-15 | Lauras As | USE OF COX-2 INHIBITORS AS IMMUNOSTIMULANTS FOR THE TREATMENT OF HIV OR AIDS |
DE10047319A1 (en) * | 2000-09-25 | 2002-04-18 | Paz Arzneimittelentwicklung | Use of R-arylpropionic acids for the production of medicaments for the treatment of diseases which can be therapeutically influenced by inhibiting the activation of the nuclear transcription factor AP-1 |
US20030027867A1 (en) * | 2001-06-29 | 2003-02-06 | Myriad Genetics, Incorporated | Use of R-NSAID compounds for anti-HIV treatment |
US20040049134A1 (en) * | 2002-07-02 | 2004-03-11 | Tosaya Carol A. | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain |
US7074826B2 (en) * | 2002-10-07 | 2006-07-11 | Encore Pharmaceuticals, Inc. | R-NSAID esters and their use |
PT1594833E (en) * | 2003-02-21 | 2008-12-03 | Chiesi Farma Spa | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases |
US20070015832A1 (en) * | 2005-07-14 | 2007-01-18 | Myriad Genetics, Incorporated | Methods of treating overactive bladder and urinary incontinence |
WO2007014124A2 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
US20070078114A1 (en) * | 2005-09-02 | 2007-04-05 | Myriad Genetics, Incorporated | Combination therapy for alzheimer's disease and other diseases |
-
2004
- 2004-07-12 AU AU2004311577A patent/AU2004311577A1/en not_active Abandoned
- 2004-07-12 JP JP2006518971A patent/JP2007528857A/en active Pending
- 2004-07-12 EP EP04821024A patent/EP1651195A4/en not_active Withdrawn
- 2004-07-12 KR KR1020067000744A patent/KR20060040676A/en not_active Application Discontinuation
- 2004-07-12 WO PCT/US2004/022339 patent/WO2005065069A2/en active Application Filing
- 2004-07-12 US US10/889,971 patent/US20050042284A1/en not_active Abandoned
- 2004-07-12 CA CA002532207A patent/CA2532207A1/en not_active Abandoned
-
2007
- 2007-02-28 US US11/680,436 patent/US20070238787A1/en not_active Abandoned
- 2007-03-01 US US11/681,082 patent/US20070238786A1/en not_active Abandoned
- 2007-05-02 US US11/743,522 patent/US20080051460A1/en not_active Abandoned
- 2007-05-08 US US11/745,928 patent/US20070293576A1/en not_active Abandoned
- 2007-07-10 JP JP2007181527A patent/JP2007262091A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of EP1651195A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
WO2006001877A3 (en) * | 2004-04-13 | 2006-02-16 | Myriad Genetics Inc | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
JP2007106732A (en) * | 2005-10-14 | 2007-04-26 | Ortec Inc | Method and composition for altering cell function |
US8865763B2 (en) | 2005-10-14 | 2014-10-21 | Alltech, Inc. | Methods and compositions for altering cell function |
US8871715B2 (en) | 2005-10-14 | 2014-10-28 | Alltech, Inc. | Use of selenium compounds, especially selenium yeasts for altering cognitive function |
EP2111868A1 (en) | 2007-10-26 | 2009-10-28 | Grifols, S.A. | Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders |
US7851446B2 (en) | 2007-10-26 | 2010-12-14 | Grifols, S.A. | Use of therapeutic human albumin for treatment of alzheimer'S disease |
EP2468270A1 (en) | 2010-12-21 | 2012-06-27 | GALENpharma GmbH | (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases |
WO2012084978A1 (en) | 2010-12-21 | 2012-06-28 | Galenpharma Gmbh | (r)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases |
US9723346B2 (en) | 2011-07-06 | 2017-08-01 | Symphony Advanced Media | Media content synchronized advertising platform apparatuses and systems |
Also Published As
Publication number | Publication date |
---|---|
KR20060040676A (en) | 2006-05-10 |
US20070238787A1 (en) | 2007-10-11 |
US20050042284A1 (en) | 2005-02-24 |
EP1651195A4 (en) | 2007-10-03 |
US20070293576A1 (en) | 2007-12-20 |
AU2004311577A1 (en) | 2005-07-21 |
US20070238786A1 (en) | 2007-10-11 |
CA2532207A1 (en) | 2005-07-21 |
WO2005065069A3 (en) | 2005-09-22 |
JP2007262091A (en) | 2007-10-11 |
EP1651195A2 (en) | 2006-05-03 |
JP2007528857A (en) | 2007-10-18 |
US20080051460A1 (en) | 2008-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080051460A1 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
EP3010506B1 (en) | Pridopidine in treating huntington's disease | |
Staskin et al. | Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial | |
Boudriau et al. | Randomized comparative bioavailability of a novel three-dimensional printed fast-melt formulation of levetiracetam following the administration of a single 1000-mg dose to healthy human volunteers under fasting and fed conditions | |
US20090068290A1 (en) | Bifeprunox doses for treating schizophrenia | |
US20100178362A1 (en) | Chromium complexes for improvement of memory and cognitive function | |
JP2009515952A (en) | Quetiapine as a controlled release formulation | |
JP2022516662A (en) | How to treat conditions associated with the S1P1 receptor | |
Abubakar et al. | Drug interaction and its implication in clinical practice and personalized medicine | |
JP2022514194A (en) | Gaboxador to reduce the risk of suicide and reduce depression quickly | |
Gibson et al. | A controlled release pilocarpine buccal insert in the treatment of Sjögren's syndrome | |
Nudell et al. | Pharmacologic management of neuropathic pain | |
Jantarabenjakul et al. | Pharmacokinetics and safety of WHO-recommended dosage and higher dosage of levofloxacin for tuberculosis treatment in children: a pilot study | |
CA3083341A1 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
AU2008201881A1 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
TW200529847A (en) | Pharmaceutical composition for use in the treatment of chronic fatigue syndrome or fibromyalgia or associated functional symptoms of fibromyalgia | |
WO2023272335A1 (en) | Cannabidiol formulation comprising a matrix pellet forming excipient | |
US10702512B2 (en) | Treatment of debilitating fatigue | |
Shaji et al. | Prescription audit of antihypertensive drugs used in stroke patients in a tertiary care teaching hospital | |
Perrot et al. | Tramadol/Dexketoprofen Analgesic Efficacy Compared with Tramadol/Paracetamol in Moderate to Severe Postoperative Acute Pain: Subgroup Analysis of a Randomized, Double-Blind, Parallel Group Trial—DAVID Study | |
Il’ina | Experience of the use of velaxin (venlafaxine) in anxious depression | |
Tamilselvan | Formulation and Evaluation of Quetiapine Fumarate Extended Release Tablets | |
JP2023543211A (en) | sustained release pharmaceutical formulations | |
WO2017146305A1 (en) | Pharmaceutical composition for treatment of depression accompanied by acute coronary syndrome | |
CN117042770A (en) | Combination therapy of obiprifepin and ezetimibe for statin intolerant patients with hyperlipidemia or mixed dyslipidemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480019922.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 544473 Country of ref document: NZ |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004311577 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006518971 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2532207 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067000744 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2004311577 Country of ref document: AU Date of ref document: 20040712 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004311577 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 291/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004821024 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004821024 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067000744 Country of ref document: KR |